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Abstract
EXPLORING THE DOPAMINE TRANSPORTER UTILIZING A TWO-PRONGED
APPROACH WITH NOVEL CATHINONE ANALOGS AND MUTANT DOPAMINE
TRANSPORTERS
By Charles Jones
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2021

Major Director: Małgorzata Dukat, Associate Professor
Department of Medicinal Chemistry

The dopamine transporter (DAT) is responsible for the removal of the neurotransmitter
from the synaptic gap and a therapeutic target for a multitude of drugs. While the ortholog
Drosophila melanogaster dopamine transporter (dDAT) and human serotonin transporter
(hSERT) have resolved structures, the human dopamine transporter (hDAT) does not. A
3-D computational homology model of hDAT was constructed for the study of molecular
interactions with agents within the central binding site (S1) of the transporter.
xvii

Synthetic cathiones are a class of abused stimulant drugs that primarily target DAT.
Greater than 150 cathinones have been identified on the clandestine market but there is
not much known about the structure-activity relationship (SAR) of these abused
compounds. A dichloro substituted benzoylpiperdine compound, part of novel series of
benzoylpiperdine cathinones, was found to be a potent DAT inhibitor. Two new
disubstituted compounds were computationally modelled, synthesized, and biologically
evaluated to investigate the effect of these substituents in DAT inhibitor potency. It was
found that all compounds were active and that the hybrids with electron donating
substituents were weaker compared to the hybrids with electron withdrawing substituents
tested.

Cathinones

based

on

the

pyrrolidinophenone

scaffold,

such

as

3,4-

methylenedioxypyrovalerone (MDPV), -pyrrolidinopentiophenone (-PVP), and 3,4methylenedioxy--pyrrolidinopropiophenone

(MDPPP),

are

established

illicit

psychostimulants. These compounds are potent inhibitors of hDAT but have little to no
activity at dDAT. In collaboration with Dr. Eltit’s lab (VCU) gain-of-function studies and in
silico modeling using mutant DAT transporters were performed. Four non-conserved
amino acid residues critical for MDPV’s high potency activity as a reuptake inhibitor at
hDAT were identified. These residues can drive MDPV selectivity not only by stabilizing
binding, but also by controlling access to its binding site.

xviii

I. Introduction
Monoamine transporters (MATs) are a family of transporters that regulate the
concentration of neurotransmitters in the synaptic gap.1 Dysfunction of these transporters
are responsible for a number of neuropsychiatric disorders.1 MATs are a target for
therapeutic agents that can treat these disorders but is also a primary target for drugs of
abuse.1 Of the three MATs, the dopamine transporter (DAT) is a specific target of abused
stimulant drugs due to dopamine’s (DA) reward pathways.1

Human DAT (hDAT) does not have a solved crystal structure therefore computational
modelling studies of this transporter must make use of homology models. Less than 20
years ago the bacterial ortholog leucine transporter had been crystallized and was
essential for the first developed homology models for hDAT. 2 Even more recently
drosophila DAT dDAT had been crystallized followed by hSERT.3,4 With the newer, more
closely related crystallized transporter structures available, a more accurate homology
model will be developed to conduct molecular modeling studies of hDAT.

Synthetic cathinones are a vast class of stimulant compounds structurally related to the
naturally occurring stimulant cathinone found in the leaves of the khat plant. 5 This group
of compounds is responsible for the majority of stimulant new psychoactive substances
(NPS) and more are emerging every year on the clandestine market. 5 While there are
numerous cathinones that are being abused, little is known about the SAR of these
compounds. Methylphenidate which is a well-known and prescribed drug for attention
1

deficit hyperactivity disorder (ADHD) has extensive SAR established.6 Efforts have
successfully been made to correlate a novel series of benzoylpiperdine cathinones that
share features with methylphenidate with known methylphenidate analogs in order to use
the known methylphenidate SAR to inform cathinone SAR. 7 In this series, it was found
that the 3,4-dichloro substituted benzoylpiperdine was the most potent, even more potent
than methylphenidate.7 To expand on SAR understanding of hDAT and to determine
which aspects cause the high potency of this disubstituted compound, two new
benzoylpiperdine compounds with varying electronic and lipophilic character will be
prepared and studied.

dDAT, which can be considered a hDAT mutant, functions the same under normal
conditions. Abused stimulant cathinones such as MDPV are highly active at hDAT but
have little to no activity at dDAT. These two transporters are closely related and share
over 50% sequence identity.3 In collaboration with Dr. Eltit’s lab, a series of mutant dDATs
were studied and it was found that with only 4 point mutations of dDAT to hDAT amino
acid residues, MDPV gained activity in the mutant dDAT similar to what is observed in
hDAT. Modelling will be performed in order to determine which amino acids are important
in these interactions and what the cause of gain-of-function is for the mutant.

Utilizing this two pronged approach where hDAT will be studied using new compounds
(cathinone hybrids) as well as using new transporters (dDAT mutants), a better
understanding of the innerworkings of hDAT can be established which is essential for the

2

development of new medications for psychostimulant dependence, attention deficit
hyperactivity, and other neuropsychiatric disorders associated with dopamine
dysregulation.

3

II. Background
A. Monoamine Transporters (MATs)
The biogenic amine (monoamine) transporters or MATs are part of the neurotransmitter
sodium symporter (NSS) and solute carrier 6 (SLC6) family. 1 They are a 12
transmembrane helix protein (Figure 1) that are Na+/Cl- dependent.1 These transporters
are found on neurons and glial cells, and are responsible for regulation of synaptic
monoamines (serotonin (5-HT), dopamine (DA), and norepinephrine (NE)) that activate
G protein coupled receptors (GPCRs) and ligand gated ion channels (LGICs). 1,8,9

Extracelluar

Intracelluar

Figure 1. Topology of monoamine transporters depicting 12 transmembrane domains
connected by intracellular and extracellular loops.10

4

Regulation occurs by the use of an electrochemical gradient to actively remove the
monoamines from the extracellular space back into the presynaptic neuron through the
transporter.1 A different transporter is primarily responsible for each corresponding
monoamine.11 SERT is responsible for 5-HT (1), NET for NE (2), and DAT for DA (3)
(Figure 2).11 Each transporter moves the appropriate neurotransmitter along with different
molar equivalent ions.1 NET uses one Na+ ion and one Cl- ion. DAT uses two Na+ ions
and one Cl- ion. SERT uses one Na+ ion, one Cl- ion, and counter transports one K+ ion.1
The intercellular potassium ion is transported to the extracellular space after the ligands
(5-HT, Na+, and Cl-) have been released intercellularly and the transporter is changing
conformation to its original state.12

5

Figure 2. A) Schematic representation of monoaminergic synaptic terminals. B) Chemical
structures of the endogenous substrates for SLC6 neurotransmitter transporters (NTTs)
and ion coupling stoichiometry for neurotransmitter reuptake.13

These transporters play a role in neuropsychiatric disorders such as attention deficit
hyperactivity

disorder

(ADHD),

depression,

orthostatic

intolerance,

epilepsy,

Parkinsonism, schizophrenia, and drug abuse.1 In 1961, Hertting and Axelrod were the
first to describe the concept of the reuptake of NE (2) by sympathetic nerve terminals.8 It
was postulated that the reuptake of neurotransmitters by a transporter was essential for
their deactivation.8 DA and 5-HT were also later shown to have similar mechanisms. 10
Countless studies have since been conducted on the function of the monoamine uptake
transporters. By the 1990s, the genes that code for the monoamine transporter proteins
6

were determined due to progress in molecular cloning techniques. 14 This facilitated the
discovery of the localization, structural and functional domains, and contributions to brain
function of the transporters using a variety of techniques such as heterologous expression
systems, mutagenesis, in vivo imaging, and animal models with disrupted monoamine
transporter genes.10

B. Structure of MATs
The first homologue of a monoamine transporter to be crystallized was the leucine
transporter (LeuT) from the bacterium Aquifex aeolicus.2 This transporter was crystallized
in 2005 and has 12 transmembrane helices with a pseudo-2-fold axis in the membrane
plane.2 This protein shares 20% identity with the eukaryotic NSSs. 2 There are currently
22 published crystal structures of LeuT with multiple drugs that are in various states of
the transport cycle. DAT, the first of the monoamine transporters to be crystallized in
2013, was crystallized from the fruit fly Drosophila melanogaster (i.e., dDAT).3 Several
point mutations (V74A, V275A, V311A, L415A, and G538L) and modifications were used
to induce the transporter to crystallize.3 Amino acid residues 1-20 as well as extracellular
loop 2 (EL2) 164-206 were removed.3 Amino acids 602–607 were replaced by a Cterminus green fluorescent protein (GFP–His8) tag with a thrombin cleavage site
(LVPRGS).3 Recombinant Human Anti-Dopamine transporter antibody antigen binding
fragment (Fab) 9D5 at a ratio of DAT:Fab 1:1.1 was also used to enhance crystallization.3
There are 14 current crystal structures of the Drosophila dopamine transporter (dDAT)
bound to both releasing agents and uptake inhibitors (Table 1). All structures are either
in the outward facing state (from inhibitors) or in the partially occluded state (from
7

releasing agents). The inward facing and occluded conformations have still not been
crystallized. The uptake inhibitors that have been crystallized are nisoxetine, reboxetine,
RTI55, win35428, cocaine, and nortriptyline.3,15 The releasing agents are 3,4dichlorophenethylamine,

methamphetamine,

and

dextroamphetamine.15

DA,

the

endogenous ligand, has also been crystallized with dDAT. 15 The dDAT crystal structure
was a leap forward in modeling the human dopamine transporter (hDAT) as it shares
greater than 50% identity.3

Table 1. dDAT crystal structures.3,15,16
Resolution
PDB

IDa

Agents

Mutation

Reference

V74A/V275A/

Penmatsa

V311A/G538L/

2013

(Å)b
Inhibitors

4M48

2.96

Nortriptyline

L415A

4XNU

2.98

Nisoxetine

V74A/V275A/

Penmatsa

V311A/G538L/

2015

L415A
Penmatsa
4XNX

3.00

Reboxetine

V74A/L415A
2015

4XP5

3.30

RTI55

8

V74A/L415A

Wang 2015

4XPG

3.21

Win35428

D121G/S426M

Wang 2015

4XPB

3.05

Cocaine

D121G/S426M

Wang 2015

4XPF

3.27

RTI55

D121G/S426M

Wang 2015

4XP4

2.80

Cocaine

V74A/L415A

Wang 2015

Releasers
3,4-Dichloro
4XPH

2.9

Wang 2015
D121G/S426M

phenethylamine
4XP6

3.10

4XPT

3.36

Methamphetamine

V74A/L415A

3,4-Dichloro

Wang 2015
Wang 2015

D121G/S426M
phenethylamine
3,4-Dichloro

4XPA

2.95

Wang 2015
V74A/L415A

phenethylamine
4XP9

2.80

Dextroamphetamine

V74A/L415A

Wang 2015

2.89

Dopamine

V74A/L415A

Wang 2015

Endogenous
4XP1
aProtein

Data Bank ID; bX-ray.

The human serotonin transporter (hSERT) was first crystallized in 2016. 4 There are
currently three different constructs of the crystallized transporter. There is the N- and Cterminally truncated wild-type (ΔN72, ΔC13), ts3 which contains the thermostabilizing
mutations Y110A, I291A, and T439S, and ts2 which is identical to ts3 without the Y110A
mutation.4 Both ts2 and ts3 also have had mutations of the surface-exposed cysteines
C554A, C580A, and C622A.4 These constructs are then fused to a C-terminus GFP and
9

then tagged with twin Strep and a decahistadine for purification. 4 Two different
recombinant antibody fragments have also been used to help crystallization, Fab 8B6 and
15B8.4 Only Apo-state hSERT and reuptake inhibitors bound in hSERT have been
crystallized. These inhibitors are Br-citalopram, (S)-citalopram (escitalopram), paroxetine,
sertraline, fluvoxamine, Br-paroxetine, and levoparoxetine.4,17-19

Table 2. hSERT crystal structures.4,17-19
PDB ID

Method

Resolution Agents

Mutation

Reference

(Å)
5I6Z

X-ray

4.53

Apo

ts2

Coleman 2016

5I74

X-ray

3.395

Br-Citalopram

ts3

Coleman 2016

5I73

X-ray

3.24

Escitalopram

ts3

Coleman 2016

5I75

X-ray

3.49

Escitalopram,

ts3

Coleman 2016

Br-Citalopram
5I6X

X-ray

3.14

Paroxetine

ts3

Coleman 2016

5I71

X-ray

3.15

Escitalopram

ts3

Coleman 2016

6AWO

X-ray

3.534

Sertraline

ts3

Coleman 2018

6AWN

X-ray

3.62

Paroxetine

S439T

Coleman 2018

6AWQ

X-ray

4.046

Sertraline

ts3

Coleman 2018

6AWP

X-ray

3.8

Fluvoxamine

ts3

Coleman 2018

6W2B

X-ray

4.7

Br-Paroxetine

ts2

Coleman 2020

6W2C

X-ray

6.3

Levoparoxetine

ts2

Coleman 2020

10

6DZW

Cryo-EM

4.3

Paroxetine

ts2

Coleman 2019

6DZV

Cryo-EM

4.2

Ibogaine

WT

Coleman 2019

6DZY

Cryo-EM

4.1

Ibogaine

ts2

Coleman 2019

6DZZ

Cryo-EM

3.6

Ibogaine

WT

Coleman 2019

6VRK

Cryo-EM

4.1

Br-Paroxetine

WT

Coleman 2020

6VRL

Cryo-EM

3.8

Levoparoxetine

WT

Coleman 2020

6VRH

Cryo-EM

3.3

Paroxetine

WT

Coleman 2020

Not only are there X-ray crystal structures but also cryo-EM structures for hSERT.
Because of cryo-EM and the non-competitive inhibitor ibogaine, all conformations
(outward facing, partially occluded, occluded, and inward facing) of hSERT have been
reported.17 Also due to citalopram orthosteric and allosteric sites of hSERT are known. 4
There are currently 19 published structures of hSERT (Table 2). NET has still not been
crystallized to date. Other unexplored crystal structures are SERT with releasing agents,
human DAT (hDAT), DAT with its occupied allosteric site, DAT occluded, DAT inward
facing, and any of the above transporter with a partial releaser.

C. Pharmacology of MATs
The regulation of the transporters has been associated with multiple neuropsychiatric and
other disorders (Table 3).

1

There are several pieces of evidence that support this

association. The first is that therapeutic agents used to treat mood disorders target DAT,
11

NET, and SERT.10 Second, monoamine transporter over expression/under expression
have been shown to be prevalent in psychiatric and neurological disorders such as
ADHD, depression, and Parkinson's disease.10 This has been determined both through
binding techniques in post mortem brain samples and brain imaging techniques. 10

Table 3. Association of SLC6 family members with substrate and human disease.1
Transporter

Human Gene

Substrate

NET

SLC6A2

Norepinephrine

Disease Association
ADHD, Anorexia nervosa,
Depression,
Orthostatic intolerance,
Cardiovascular disease

DAT

SLC6A3

Dopamine

Addiction, ADHD,
Major affective disorder,
Parkinson’s disease,
Tourette’s syndrome

SERT

SLC6A4

Serotonin

Anxiety, Autism, Depression,
Gastrointestinal disorders,
Obesity, OCD,
Premature ejaculation,
Schizophrenia

12

D. Transporter Ligands and Drugs of Abuse
All agents that are affiliated with the monoamine transporters work under three modes of
action. First, the endogenous ligands are substrates for the transporters and are cotransported with ions through the transporter into the cell. 13

The second type are

inhibitors that will bind to the transporter in its outward facing state and prevent the
transition to an occluded state.13 The third type of agent’s, known as releasers, mode of
action is substrate-like but they also induce a reverse function of the transporter causing
an efflux of endogenous monoamine neurotransmitters extracellularly (Figure 3).20 Once
the transporter is in the inward state releasing the agent intracellularly, endogenous
ligands are then transferred in the reverse direction extracellularly.20 There is a subclass
of these releasers that are known as partial releasers.21 They function like releasers but
are not nearly as efficacious.21

13

Figure 3. Representation of uptake versus releaser efflux cycle. T o is the transporter
facing outward. Ti is the transporter facing inward.21

The inhibitors make up the largest variety of these agents on the market. Many drugs of
abuse directly affect the transporters. Of this category of drugs, all act either as a releaser
or an inhibitor. Both types of agents have the same outcome with an overall increase in
synaptic concentration of neurotransmitter.

14

1. Releasers
The most widely abused and infamous releasers are amphetamine (AMPH, 4) and
methamphetamine (5). Both these agents are Schedule II in the United States. As such,
they have limited medical use but a high potential for abuse, with use potentially leading
to psychological or physical dependance.22 The severe behavioral effects of these agents
are related to the release of excess DA into the synaptic cleft of dopaminergic neurons.23
N-Methylated AMPH, that is, methamphetamine (5), has been shown to have increased
potency compared to AMPH.23

Figure 4. Structures of selected releasing agent drugs of abuse.

The chewing of khat leaves (Figure 5) has been practiced for hundreds of years in middle
eastern countries to produce a stimulant effect.24 The stimulant effects are primarily due
15

to the chemical agent cathinone (6), a naturally occurring psychoactive alkaloid that is a
beta ketone analog of amphetamine (4) as well as a potent releasing agent.24

B.

A.

Figure 5. A) A field of khat plants. B) A bundle of fresh khat leaves.25

The first synthetic cathinone derivative reported was methcathinone (7) in 1928,26
although the term “methcathinone” was not coined until 1987. 27 Like amphetamine (4)
increasing in potency with N-methylation to methamphetamine (5), methcathinone (7)
was considered in the same vein with N-methylation of cathinone (6).27 The recreational
use of methcathinone (7) has been mostly reported in former USSR countries but gained
popularity in the USA during the 1990s.24,28 Recently the majority of new psychoactive
substances (NPS) that effect the monoamine transporters are synthetic cathinones. 29
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They are usually sold as "legal highs" and multiple synthetic cathinone analogs have
gained prominence starting around 2007.29

2. Inhibitors
The most infamous inhibitor drug of abuse is cocaine (8) which is the major active
stimulant of the coca leaf (Erythroxylon coca).30,31 The leaf is widely used and chewed in
South America as an anti-fatigue agent.30 While cocaine itself is a Schedule II drug with
legitimate medical use, there is a worldwide drug abuse problem with it. 31 Cocaine (8) is
a nonselective inhibitor across all three MATs, but the main action that contributes to
cocaine’s (8) and all inhibitor drug of abuse’s abuse potential is the inhibition of DAT
allowing for an increase of DA concentration in the synaptic cleft of dopaminergic
neurons.31

Figure 6. Structures of selected reuptake inhibitor drugs of abuse.
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Methylphenidate (9) is another well-known inhibitor drug with high potential for abuse. 32
Like cocaine, it is Schedule II.33 It differs in the fact that it has little to no activity at SERT
and is much more selective for the other two MATs, DAT and NET.34 Synthetic cathinones
have been found to be inhibitor drugs of abuse as well. 3,4-Methylenedioxypyrovalerone
(MDPV, 10) was the first popularly abused synthetic cathinone found to be an inhibitor.35
MDPV (10) is more potent than both cocaine (8) and methylphenidate (9) at DAT and was
placed under Schedule I as of 2011. 33,36,37 -PVP (11), the des-methylenedioxy analog
of MDPV (10), started appearing more often on the clandestine market after the ban on
MDPV and its sale was first restricted in 2014.33,38 -PVP (11) is about equipotent to
MDPV (10) and like both methylphenidate (9) and MDPV (10) is highly selective for DAT
and NET.39

3. Partial Releasers
Partial releasers, a sub class of releasers, display their partial release characteristics due
to inducing neurotransmitter efflux at a slower rate than full releasers. 40 This unique
property presents compounds with lower EMAX which is the maximum response an agent
can produce compared to the full releaser D-amphetamine.40 Compounds 12 and 13 have
both been identified as partial releasers.40 Compound 12 has an EC50 of 622 nM but its
EMAX is only 61%.40 Likewise, 13 presents an EC50 of 1207 nM and an EMAX of 66%.40 The
EMAX of both compounds is much lower when compared with the full releaser AMPH with
an EMAX of 103%.40
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The exact mechanism underlying the action of partial releasers remains unknown.
However, the “partial release” by certain agents might be assay related. For example,
some substituted AMPH analogs that behave as partial releasers in a synaptosome assay
were shown to act as reuptake inhibitors in a two-electrode voltage clamp assay using
hDAT.41

Figure 7. Structures of selected partial releasing agents.40

The possible therapeutic applications of partial releasers are still undetermined. Partial
releasers have been shown to display less abuse liability.41 These types of compounds
have the potential to be developed into useful drugs due to their lower abuse potential.

E. Assay Methods
A variety of methods have been used to characterize MAT releasing agents and reuptake
inhibitors. The information that each assay exhibits makes up the majority of what is
known about DAT and agents that act at DAT. Here only two methods will be described
19

in detail. The first assay is the APP+ inhibition assay.42 It allows the characterization of
both inhibitors and releasers but does not differentiate between the two. 42 The second
assay is the Ca2+ flux assay.43 This assay is a more recent development and allows for
the differentiation between releasers and inhibitors.43

1. APP+ ASSAY
One method for examining possible emerging stimulant drugs of abuse is using an APP+
inhibition assay. This assay uses human embryonic kidney (HEK) 293 cells with an
overexpression

of

the

transporter

of

interest.

4-(4-Dimethylamino)phenyl-1-

methylpyridinium (APP+, 14) is a fluorescent compound that is a substrate for the
monoamine transporters (Figure 8).44 It is only fluorescent when transported within the
cell.44 This is primarily due to the conformation the molecule takes intracellularly which
increases its conjugation and lowers the excitation band gap. 45 The assay proceeds by
exposing the cells to an agent of interest followed by a mixture of the agent and APP +
(14).42 If a dose dependent decrease of fluorescence is observed the agent of interest is
competitively inhibiting APP+ from interacting with the transporter.42 Through this method
both releasing agents and inhibitors are able to be examined for functional activity but not
differentiated. Figure 8 depicts the fluorescence of APP+ when interacting with HEK293
cells stably expressing hDAT. Each amorphous circle is a cell and the bright white color
is the fluorescence emitted at a wave length of 540 nm using an excitation wave length
of 460 nm pictured through the microscope.
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Figure 8. Structure of APP+ (14) and fluorescence of HEK293 cells stably expressing
hDAT exposed to APP+.

2. Ca2+ Flux Assay
A calcium flux assay can be used to distinguish the two types of agents. In this assay
HEK293 cells expressing the MAT transporter of interest are also transiently transfected
with voltage gated calcium channels (Cav1.2) .43 Fura2 is a membrane permeable
fluorescent dye that only fluoresces upon binding to intracellular calcium ions.43 The
assay is carried out by exposing the cells to fura2 and then washing away the excess
solution.43 The agent of interest is then perfused to the cell and fluorescence is measured
using a fluorescence microscope.43 Upon a substrate being transported intercellularly,
the cell becomes depolarized causing the calcium channels to open and a flux of calcium
ions enter the cell (Figure 9).46 These ions interact with the intracellular fura2 and cause
21

fluorescence to occur.43 Inhibitors however, block the transporter thereby disallowing any
depolarization to occur and the calcium channels stay closed. 43 No fluorescence is
observed for the inhibitors.43 The potency of inhibitors can be measured by inhibition of
DA.

Figure 9. Releasers (e.g., AMPH, 4) cause Ca2+ efflux by Ca2+ channel activation
through cellular depolarization. Inhibitors (e.g., MDPV, 10) do not activate Ca2+
channels.46

F. Cathinone SAR
After the discovery of the stimulant effects of cathinone from the khat plant several other
synthetic cathinone compounds were found to have stimulant effects. 5,47 Early studies
using rabbit synaptosomes pretreated with [3H]DA showed that cathinone (6) was a
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releasing agent.48 Later it was found that of the two possible isomers of cathinone (6) the
S isomer 6s was more potent than the R isomer 6r in drug discrimination studies.49

Figure 10. Structures of the two isomers of cathinone (6).

The first synthetic cathinone, methcathinone (7) was found to be even more potent than
cathinone.27 Many other synthetic cathinones have been examined for activity with
modifications at the phenyl ring (R1), alpha carbon (R2), and the amine (R3) (Figure 11).5

Figure 11. Structure of cathinone (6; R1=R3=H, R2=CH3) and numbering and position of
substituents.
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1. Aryl Substitution
Few ring substitutions have been examined for cathinone (6). Of the agents tested 1518, all failed to produce locomotor stimulation in mice.50 Compound 19 failed to generalize
in rats trained to discriminate cathinone (6) from saline vehicle while 20 showed partial
generalization.51

Figure 12. Structure of cathinone analogs with selected aryl substitutions.

Compound 21 produced partial generalization for amphetamine (4) trained rats but fully
substituted in rats trained with the empathogen N-methyl-1-(3,4-methylenedioxyphenyl)-
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2-aminopropane (MDMA).52 Several ring substitutions have been examined for
methcathinone (7) as well.30

Figure 13. Structure of methcathinone analogs with selected aryl substitutions.

Compound 22 stimulated locomotor activity in rats at 10 mg/kg, double the dosage of
methcathinone (7), 5 mg/kg.53 Analogs 23 and 24 were found to not produce any
hyperactivity at all doses tested.53,54 The cathinone analog of MDMA, 25, generalized for
both amphetamine (4) trained rats and MDMA trained rats.52 It was, however, 6-fold less
potent than methcathinone (7) in the amphetamine (4) discrimination assay.

52

Mephedrone (26) has been shown to be a DA releasing agent with a similar EC 50 (1.19
M) but with less percent of maximum release (68%) when compared to methcathinone
25

(7) (3.57 M, 83.3%) in a [3H]DA release assay using HEK-293 cells expressing hDAT.55
Compound 27 on the other hand, exhibited opposite behavior to mephedrone (26) with a
larger EC50 (17.8 M) but a higher percent maximum release (98%).55

2. -Methyl Modification
-Desmethylcathinone (28) was not active and failed to substitute at up to 10 times the
ED50 dose of cathinone (6) both in rats trained to discriminate amphetamine (4) and rats
trained to discriminate cathinone (6) from saline vehicle.49,51 When tested as a releasing
agent with [3H]DA in rat synaptosomes, 28 was found to be about one-fourth to one-third
as potent as cathinone (6).56,57

Figure 14. Structure of cathinone analogs with selected -methyl modifications.

Conformationally constraining the -methyl group into a ring 29 also failed to substitute
at 10 times the ED50 dose of cathinone in discrimination studies.56 Analog 29 was about
one-fifth as potent as cathinone in a tritiated DA release experiment. 56
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3. Amine Modification
Homologation at the amine beyond N-methyl to N-ethyl (i.e., 30) and N-propyl (i.e., 31)
lowered stimulant potency in drug discrimination studies.52

Figure 15. Structure of cathinone analogs with selected amine modifications.

Increased branching of the amine substituent with an isopropyl group (i.e., 32) or tertbutyl (i.e., 33) resulted in diminished potency in locomotor activity assays compared to
methcathinone (7).53 It was also found N,N-dimethylcathinone (34) was about half as
potent as methcathinone and it was later discovered that in human subjects about 45%
of this agent is metabolically converted to methcathinone (7) when taken orally.52,58
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4. Inhibitor Cathinone Deconstruction
MDPV (10) being the first DAT inhibitor cathinone found on the clandestine market
promoted research on the deconstruction of this cathinone to examine the structural
features that contribute to its DAT inhibitory effects.59 All MDPV (10) deconstruction
analogs tested behaved as DAT reuptake inhibitors although with varying degrees of
potency (Figure 16).39 MDPV (10) itself was found to be the most potent.39
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Figure 16. Deconstruction of MDPV (10). IC50 values represent potency to block
reuptake of DA. Each arrow represents one structural modification. 39

The loss of the methylenedioxy ring to form -PVP (11) showed little change in inhibitory
activity compared to the parent compound which provides evidence that the ring is not
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necessary.39 All other deconstructions (i.e., 35-40) were much less potent than MDPV
(10).39 Removal of the carbonyl oxygen (i.e., 35) showed around a 10-fold loss in
potency.39 This is unique for inhibitor drugs of abuse as a large potency drop is not seen
in the releasing agents (i.e., methcathinone (7) to methamphetamine (5)).60 The other
analogs reduced potencies demonstrate the two most important features for high DAT
inhibition activity. The first is bulk of the pyrrolidine ring. Alteration of this ring to a simpler
tertiary (i.e., 36), secondary (i.e., 37), or primary (i.e., 38) amine greatly reduces DAT
inhibition potency in a stepwise manner with the primary amine 38 being the weakest
inhibitor compound.39 The second most important feature is the extended -alkyl side
chain. Truncation of this chain alone (i.e., 39) reduces potency by 25-fold.39 Modification
to both the pyrrolidine ring and the alkyl side chain (i.e., 40) showed the second largest
drop in potency with an IC50 of 22,300 nM.39

5. Inhibitor Cathinone Elaboration
-PVP (11), the des-methylenedioxy analog of MDPV (10) and roughly equipotent in DAT
inhibition, was used as a scaffold in a series of elaborations to explore the SAR of the
alkyl side chain and the pyrrolidine ring size of these inhibitor cathinones (Table 4).61 It
was found that reducing the length of the side chain (i.e., 41-43) decreased potency in a
stepwise manner.61 Branching from n-propyl (i.e., 11) to iso-propyl (i.e., 44) reduced
potency as well.61 Elongation from n-propyl (i.e., 11) to n-butyl (i.e., 45) increased
potency.61 Adding a cyclopentyl ring (i.e., 46) was equipotent to the parent compound
while elaboration to a cyclohexyl ring (i.e., 47) increased potency and was the most potent
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compound of the series.61 Modifying the pyrrolidine ring to a piperidine ring decreased
potency for both compounds tested (i.e., 48, 49).61 As seen with other cathinones
conformationally constraining the alkyl side chain back to the aryl ring (i.e., 50) showed a
large drop in potency.61

Table 4. Inhibition of [3H]dopamine uptake in synaptosome assay by elaborated
analogs of -PVP (11).61

Compound

-R

IC50, nM

41

-H

3250.0

42

-CH3

196.7

43

-CH2CH3

63.3

11

-CH2CH2CH3

17.5

44

-CH(CH3)2

92.3

45

-CH2(CH2)2CH3

11.6

46

-C5H9

17.1

47

-C6H11

8.3

48

-CH3

31

2490.0

49

-CH2CH2CH3

50

128.0
12900.0

To summarize what is currently known about the SAR of cathinones: by adding bulk to
the alpha carbon (R2) or changing the primary amine to a bulky secondary or tertiary
amine (R3) caused the action of these agents to change from a releaser to an inhibitor
(Figure 11).5 Also, selectivity for the different transporters can be affected through
molecular modification. Cathinone (6) is a releaser for all of the monoamine transporters.5
Adding bulk onto the alpha carbon (R2) shifts selectivity more towards DAT and NET.5 In
contrast, adding a methylenedioxy ring or a trifluoromethyl substituent on the aromatic
ring (R1) shifts the selectivity of the compounds more towards SERT than DAT or NET.5,12
All these different alterations to the backbone of the molecules do interplay with each
other. MDPV (10), the potent DAT inhibitor, that has the methylenedioxy ring on the
aromatic ring (R1) has no activity towards SERT due to its large alpha alkyl side chain
(R2) and its tertiary amine (R3) from the pyrrolidine ring.5 Cathinone (6) has a chiral center
as well () (Figure 11). The stereochemistry does affect the overall potency of cathinones.
Both R and S isomers have been shown to be active with S being shown to be the eutomer
in most cases.5
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G. Methylphenidate SAR
Methylphenidate (9), a well-studied and widely prescribed drug on the market, is primarily
used for the treatment of ADHD.62 It was first synthesized in 1944 but was not discovered
to have stimulant activity until 10 years later.63,64 The first clinical use of methylphenidate
(9) was as an analeptic from barbiturate-induced coma.41 The original patent of
methylphenidate (9) was for its preparation by CIBA pharmaceuticals in 1950 then later
patented for method of use in 1954 as a treatment of psychiatric disorders. 65 It has a bulky
secondary amine and an extended alpha alkyl side chain that connects back to the amine
to make up a piperdine ring. These features contribute to the compound’s character as
an inhibitor that is selective towards DAT and NET as well as showing little to no activity
at SERT.66 There are four stereoisomers of methylphenidate (9) (Figure 17) and there is
a high eudysmic ratio between the RR and SS enantiomers. 67 Dexmethylphenidate (dthreo-methylphenidate), the RR enantiomer of methylphenidate (9), is the eutomer of the
four isomers.6,67,68

Figure 17. Four stereoisomers of methylphenidate (9).
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A crystal structure of the inactive conformation of l-threo-methylphenidate (9) has been
solved (Figure 18) with the monoclinic crystal in the P21 space group.69 In addition, with
the use of this crystal and the MM2-87 program a global minimum of the active d-threomethylphenidate (dt9) was also obtained.69 In the active d-threo-methylphenidate (dt9)
conformation it can be observed that the protonated piperidine nitrogen can form an
interaction with the carbonyl oxygen at a distance of 3.32 Å. 69

Figure 18. (A) Global minimum of d-threo-methylphenidate (dt9) (B) Solved crystal
structure of l-threo-methylphenidate (lt9).69

The chemical space of methylphenidate has been explored exhaustively (Figure 19).6 A
quantitative SAR analysis of 80 methylphenidate (9) analogues has previously been
conducted.6
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Figure 19. SAR features that have been quantitatively explored for dt9.70

Substituents have been added and tested on the aromatic ring, the ester has been
modified, and the piperdine ring has been added to as well as ring size altered (Figure
19).6 All further discussion of methylphenidate analogs will be concerned with the racemic
mixture of threo-methylphenidate (t9).

1. Aryl Substitution
A series of aryl substituted analogs of methylphenidate (9) were examined for [3H]WIN
35,428 binding and [3H]DA uptake.6,71 All 2-substituted compounds had weaker binding
and were less potent than t9 at uptake inhibition.71 In the 3-position all halogens and
hydrophobic groups evaluated were more potent than t9 while all hydrophilic electron
donating groups (EDG) were less potent.71 The 4-position reveals a similar trend as the
3-position substituents having halogens and hydrophobic groups showing more potency
than t9 but with less increases in potency.71 A hydrophilic EDG, 4-NH3•HCl analog (i.e.,
73), was twice as potent as t9 indicating that hydrophobicity and electronic character may
not be responsible for potency at the 4-position but instead volume of the substituent.71
35

Table 5. DAT binding affinity (IC50, nM) and uptake inhibition potency (IC50, nM) of aryl
substituted methylphenidate (9) analogs 51-79.6,71

Compound

-R

Bindinga (IC50, nM)

Uptakeb (IC50, nM)

t9

-H

83

224

51

2-F

1420

2900

52

3-F

41

160

53

4-F

35

142

54

4-CF3

615

-

55

2-Cl

1950

2660

56

3-Cl

5

23

57

4-Cl

21

74

58

3,4-diCl

5

7

59

3,5-diCl

67

-

60

2-Br

1870

3410

61

3-Br

4

13

62

4-Br

7

26

63

4-I

14

65

64

2-OH

23100

35800

36

65

3-OH

321

790

66

4-OH

98

340

67

2-MeO

101000

81000

68

3-MeO

288

635

69

4-MeO

83

293

70

3,4-diMeO

810

1760

71

4-NO2

494

1610

72

3-NH2•HCl

265

578

73

4-NH2•HCl

35

115

74

3-Me

21

100

75

4-Me

33

126

76

3,5-diMe

4690

-

77

4-Et

737

-

78

3,4-benzo

11

53

79

4-t-Bu

13500

9350

a[3H]WIN

35,428 radioligand. b[3H]DA substrate.

Also, there was an exception of 4-NO2 and 4-t-Bu analogs (i.e., 71 and 79) being less
potent than compound t9 suggesting that there is a limit to the size of the substituents at
the 4 position.71 A hydrophobic electron withdrawing group (EWG), 4-CF3 analog 54, with
a similar size to 4-Me and 4-Cl, was less potent than compound t9.6 This substituent has
a higher polarizability or negative hyperconjugation that might explain the difference seen
in 4-CF3 from the other substituents at the 4-position. For disubstituted compounds, 3,4
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and 3,5 were the only positions tested.6,71 All disubstituted compounds evaluated saw an
increase in potency from EWGs and a decrease in potency from EDGs compared to
(t9).6,71

2. Amine Substitution
Alkylation of the piperidine amine group has been examined.6 Alkylation such as methyl
80, allyl 81, and propynyl 82 reduced affinity.6 Addition of benzyl type groups had mixed
results (i.e., 83-94). The only substitutions that had better binding than compound t9 were
benzyl 83 and p-Cl-benzyl 92. p-MeO-Benzyl (94) was similar in potency to t9 whereas
all other benzyl substitutions were weaker.
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Table 6. [3H]WIN 35,428 binding affinities (IC50, nM) of methylphenidate (9) analogs
with amine substituents.6

Compound

-R

(IC50, nM)

t9

-H

83

80

-CH3

499

81

-CH2CHCH2

597

82

-CH2CCH

821

83

-Bn

84

-MeBn

678

85

-EtBn

267

86

-PrBn

205

87

-BuBn

1570

88

-PeBn

656

89

-Bn-p-NCS

422

90

-Bn-m-Cl

106

91

-Bn-o-Cl

243

92

-Bn-p-Cl

31

93

-Bn-p-NO2

113

94

-Bn-p-MeO

79

39

53

95

-2-Pyridyl

369

96

-3-Pyridyl

173

97

-4-Pyridyl

128

98

-2-furyl

536

99

-3-furyl

459

100

-2-thienyl

224

101

-3-thienyl

143

2-, 3-, and 4-Pyridyl groups were also examined (i.e., 95-97) of which all were weaker in
comparison to t9.6 Likewise, 2- and 3-furyl 98, 99 and thienyl 100, 101 analogs were
tested as well with weaker affinities.6

3. Ester Modifications
Several substituents have been examined in place of the ester group on methylphenidate
(t9) (Table 7).6,72 All modifications tested showed lower affinity when compared to the
parent compound.6,72 The methyl Et2O 103 was the only compound tested with a similar
binding affinity to methylphenidate (t9).6
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Table 7. [3H]WIN 35,428 binding affinities (IC50, nM) of ester-modified methylphenidate
(9) analogs.6,72

Compound

-R

(IC50, nM)

t9

-CO2CH3

83

102

-CH2OH

448

103

-CH2OCH3

104

-CO2Bn

105

-CH2O(CO)CH3

106

-CO2NH2

1730

107

-H

6360

97
1020
690

4. Ring Modifications
Modification of the piperidine ring has also been explored from a 5-membered ring all the
way up to an 8-membered ring as well as a change to a morpholine ring (Table 8).73 The
piperidine ring of t9 was the most efficacious followed by the 7-membered ring analog
which had 2-fold lower affinity and 3-fold lower potency.73 While the morpholine analog
contains a 6-membered ring like the parent compound t9, it had the lowest affinity and
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activity of all the analogs tested.73 It can be concluded then that the oxygen atom of the
morpholine ring is not well tolerated by DAT.73

Table 8. DAT binding affinity (IC50, nM) and uptake inhibition potency (IC50, nM) of
piperidine ring modified methylphenidate (t9) analogs 108-111.73

Compound

Ring Size

Bindinga (IC50, nM)

Uptakeb (IC50, nM)

108

5

355

885

t9

6

83

224

1250

9930

109

6-morpholine

110

7

197

701

111

8

623

1590

a[3H]WIN

35,428 radioligand. b[3H]DA substrate.
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Of all the modifications explored for methylphenidate, only EWG substitutions at the meta
or para position that are within the plane of the phenyl ring correlate with increased DAT
affinity and activity.6 Large substituents in the ortho position, substituents above and
below the plane of the aryl ring, substitutions on the piperdinyl nitrogen atom, and
decreasing polarity near the carbonyl moiety all correlated with decreased DAT activity. 6

H. New Methylphenidate/Cathinone Hybrids
Portoghese proposed that if two different series of compounds with the same change in
substituents have parallel changes in binding affinity then they likely bind in a similar
manner.74 With the large number of synthetic cathinones coming onto the grey market as
drugs of abuse, is it possible to predict new cathinone activity by using the SAR of the
well-studied

methylphenidate

compounds?

Our

lab

cathnione/methylphenidate compound (i.e., 112; Figure 20).7
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developed

a

hybrid

Figure 20. Cathinone (6)/methylphenidate (t9) hybrid compound 112.7

The hybrid 112 has the ketone of cathinones as well as the piperidine ring of
methylphenidate. The hybrid was evaluated for reuptake inhibition using the APP + assay
as well as for DAT releaser or inhibitor properties using the Ca2+ assay (Figure 21).7 It
was found that the hybrid 112 was active, but less potent than methylphenidate (t9), at
reuptake inhibition.7
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Figure 21. Ca2+ efflux assay of selected hybrid compound 112 showing DAT inhibitor
properties.7

It was also determined that 112 was not a releaser and shared the inhibitor properties of
methylphenidate (Figure 21).7 Using a series of 8 hybrid compounds (i.e., 112-119) it was
shown that parallel activity existed in substituent alterations at the aromatic ring of the
hybrid compound’s potencies compared to the corresponding methylphenidate analog’s
binding affinities (Table 9).7
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Table 9. DAT uptake inhibition potency (IC50, nM) of aryl ring modified hybrid (i.e., 112)
compounds and DAT binding affinity (IC50, nM) of corresponding aryl-ring modified
methylphenidate (9) analogs.7

Hybrid

-R1

-R2

Uptake (IC50, nM)

t9 Analogs

Compound

Binding
(IC50, nM)

112

-H

-H

1080

9

83

113

-CH3

-H

380

75

33

114

-C2H5

-H

6900

77

737

115

-Cl

-H

520

57

21

116

-Br

-H

590

62

7

117

-OCH3

-H

2340

69

83

118

-CF3

-H

14300

54

615

119

-Cl

-Cl

47

58

5

aAPP+

substrate. b[3H]WIN 35,428 radioligand.

A plot comparing the hybrid series inhibition pIC50’s to the affinity pIC50’s of the
methylphenidate analogs revealed a correlation coefficient of 0.91 (Figure 22). 7
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Figure 22. Correlation (r = 0.91) of APP+ uptake assay data of hybrid (i.e., 112)
compounds and binding data of methylphenidate (t9) analogs.7
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III. Specific Aims and Rationale
A. Project 1.
Aim 1. Construct a new hDAT homology model
DAT is an important transporter that is implicated in a multitude of neuropsychiatric
disorders. The function and crystal structures of MATs has only been established in the
past 20 years. Even with the advancements in structural biology, hDAT has still not been
crystallized. In order to better understand this important transporter several different
methods will be used to approach the exploration of hDAT from different perspectives.
One strategy is to understand how novel agents (see below) bind at hDAT, and the
second is to examine several known DAT reuptake inhibitors at dDAT mutants
transitioning from dDAT to hDAT. Both of these projects will utilize a new DAT homology
model that we propose to construct. Hypothesis: Using the most recent MAT
homologues with high identity compared to hDAT it should be possible to develop a more
accurate model than what has been used in the past. Using this new homology model,
docking and HINT analysis can be used to study the innerworkings of hDAT.
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Aim

2.

Elucidate

factors

determining

the

potency

of

3,4-disubstituted

cathinone/methylphenidate hybrids
a. Synthesis
Synthetic cathinones are a newer drug abuse problem that is causing alarm worldwide.
With greater than 150 synthetic cathinones already identified and even more emerging
every year there is great interest in better understanding the SAR of these compounds.
MDPV (10) was the first discovered abused reuptake inhibitor synthetic cathinone. What
is known about the SAR of the DAT reuptake inhibitor cathinones mainly involves the
nature of the bulky amine and extended -alkyl side chain. Little is known about
substituents around the aryl ring. Methylphenidate (9) is a well-known DAT reuptake
inhibitor with extensive SAR established. Our lab developed a cathinone/methylphenidate
hybrid that exhibits DAT reuptake inhibition. A series of these hybrid compounds was
developed and used to explore DAT SAR in comparison to corresponding
methylphenidate analogs. The most potent compound of the hybrid series (i.e., 112) was
shown to be even more potent than methylphenidate: the 3,4-dichlorobenzoylpiperdine
analog 119. What is it about this compound that makes it so potent? To exam this
phenomenon we designed two additional hybrid compounds that will help elucidate why
the dichloro substituents of 119 increase DAT inhibition potency (Figure 23).
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Figure 23. Structures of hybrid compound 112,74 potent hybrid compound 119,74 and
two proposed new compounds 120 and 121.

The two new compounds take into account steric, electrostatic, hydrogen bonding, and
halogen bonding effects (Table 10). The first compound is 3,4-dimethylbenzoylpiperdine
120. The two methyl groups are about the same size as the chloro groups of 119 but with
opposite electronic character. Chloro groups are weakly electron withdrawing while
methyl groups are electron donating. Hypothesis: If electronic character is driving the
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increase in activity the 3,4-dimethylbenzoylpiperdine 120 should be less potent than the
dichloro 119 compound. If electronic character is not important for activity, then the
dimethyl compound should have similar activity. The second compound is the 2naphthoylpiperdine 121. This compound has the additional conjugated ring to the phenyl
ring at the 3,4 positions.

Table 10. Lipophilic (), electronic (), steric (Vol), hydrogen bond (HB) acceptor, and
halogen bond formation properties of compounds 119-121.
Parameter

119

120

121



1.46a

1.03b

1.32a



0.60c

-0.24c

0.08a

Vol (Å3)d

90.9

88.2

100.0

HB Acceptor

Yes

No

Yes

Halogen Bond

Yes

No

No

a Values

as reported by Hansch et al.75 b Values as reported by Fujita et al.76 c Values as

reported by Jaffé.77 d Volume measured using SybylX 2.1.1.

It is slightly larger in size compared to the dichloro substituents of 119 and has similar
electron withdrawing character. It is usually seen as a bioisotere for 3,4-dichlorophenyl
substituents. What is different about 121 is that it does not have the ability to form halogen
bonds. This halogen bond activity is due to the anisotropic nature of halogen substituents.
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The halogen forms a -hole that has positive electronic nature and can be viewed as a
Lewis acid (Figure 24). This -hole can then interact with a Lewis base such as a lone
pair from a hetero atom. Hypothesis: If 121 is less potent than the dichloro compound
119 then the dichloro compound might have increased potency through hydrogen or
halogen bond formation. If the naphthoyl compound 121 has similar potency to the
dichloro compound then halogen bond formation is less likely and only the size (i.e.,
volume) of the substituents, hydrogen bonding, or possibly electronic  character is
important for activity. The extended aromatic ring of compound 121 has a delocalized 
cloud above and below the face of the ring (Figure 24). This  cloud has negative
electronic character and can participate in interactions with positively charged species
such as hydrogen bond donors.78 This can be viewed in the same way as edge-to-face
interactions of aromatic rings.

52

Figure 24. Representation of positive and negative electrostatic interactions involving a
halogen bonds (above) and aromatic rings (below).

b. Biological Studies
After the synthesis of each target compound (i.e., 120, 121) the APP+ assay will be used
to evaluate their potencies. HEK Flp-In T-REx 293 cells stably expressing hDAT will be
cultured and plated in a 96-well plate. Using an imaging solution, selected concentrations
of the target agents will be constantly perfused followed by a mixture of the target agent
and APP+. The entire experiment will be observed and recorded using fluroescence
microscopy. Data obtained through the recording will then be analyzed and inhibtion IC 50
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plots will be generated. Compound 119 will be resynthesized and used as control in this
assay.

c. Docking
After developing a hDAT homology model all three compounds will be docked and scored
using Hydrophilic INTeraction (HINT) analysis. On a molecular level, the specific
interactions with the amino acids within hDAT and the compounds will be examined. The
particular substituent properties important for increased or decreased hDAT reuptake
inhibition can then be possibly elucidated. The modeling data will then be compared to
the biological data and new insights on cathinone reuptake inhibitor SAR will be
established.

B. Project 2.
Aim. Evaluate binding modes of selected cathinones at DAT mutant transporters
utilizing 3D molecular modeling
Another approach to better understand DAT is mutagenesis. dDAT might be thought of
as a natural mutant to hDAT that might display unique SAR with cathinone reuptake
inhibitors. While both dDAT and hDAT transport the endogenous ligand DA with similar
potencies, the potent hDAT cathinone reuptake inhibitor MDPV (10) is essentially inactive
at dDAT (DeFelice, unpublished data). Evidently, structural differences between dDAT
and hDAT must account for this difference. In a collaboration with Dr. Eltit’s lab, using
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constructed four point mutations transitioning dDAT to hDAT, three synthetic cathinones
known to be effective hDAT reuptake inhibitors will be examined at the dDAT mutant
transporters: MDPV (10), -PVP (11), and MDPPP (39) (Figure 25).

Figure 25. Structures of agents to be examined at dDAT mutant transporters: MDPV
(10), -PVP (11), and MDPPP (39).

Compounds 11 and 39 might be viewed as deconstructed analogs of MDPV (10).
Compound 11 lacks the methylenedioxy ring of 10 whereas 39 possesses a shorter side
chain. Evaluation of these compounds will assist in determining which of these two
structural features (i.e., the methylenedioxy ring or the extended side chain) account for
the difference in action of MDPV (10) at dDAT versus hDAT.
Hypothesis: As the structure of dDAT transitions to hDAT favorable molecular
interactions between ligand and protein should improve.
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Using the previous (see Project 1) generated hDAT homology model and in addition the
crystal structure of dDAT and a mutant model with the four mutations, docking studies
and HINT analysis on all three agents within the models will be performed.

Overall, this two-pronged approach, which can be summarized by Figure 26, will help
develop a better understanding of the innerworkings of DAT.

Figure 26. Summary of two-pronged approach to better understand DAT.
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IV. Results and Discussion
A. Project 1.
Aim 1. Construct a new hDAT homology model
There is no crystal structure of hDAT, thus, a homology model of hDAT was constructed
using MODELLER 9.24. This software package makes use of a crystal structure template
and the amino acid sequence of the protein of interest. For this particular hDAT homology
model three separate crystal structure templates were used. The reason for multiple
templates is based on three criteria: the highest sequence identity, the largest query
coverage, and a crystal structure with a similar test ligand. The highest sequence identity
allows for the most similar structure to be formed during the model build. The largest
query coverage ensures places where there could be gaps or high amounts of ambiguity
for model generation are minimized. Using a crystal structure that has a similar test ligand
can help ensure that in docking studies proper interactions will take place between an
agent of interest and the amino acids within the binding pocket. PDB ID: 4XPB, a dDAT
crystal structure, was used due to having the highest sequence identity with hDAT at
55.35%. This is a large improvement from previous models developed from the ortholog
LeuT having only a 24% identity to hDAT.79 Also, homology model generation usually
needs at least 30% identity to produce an adequate model otherwise there can be
significant alignment errors and main chain positions can be greatly altered.80 PDB ID:
6VRH, an hSERT crystal structure, was used due to having a 92% query coverage. 81
Having such a large query coverage crystal structure template that is in the SLC6 family
with hDAT helps ensure that the portions of the protein that are missing from the dDAT
crystal structure can still be sufficiently modeled. Lastly, PDB ID: 4XPT was used because
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its co-crystallized ligand was 3,4-dichlorophenethylamine that has chloro substituents on
the phenyl ring that correspond to the ones found in compound 119. Utilizing this crystal
structure that has amino acids within the binding pocket possibly interacting with the two
chloro groups in the same manner as the chloro groups from compound 119, should have
considerable benefits when docking compounds 119, 120, and 121. The target hDAT
sequence was obtained from NCBI accession BAA22511.1. Using this target sequence
and the three templates, MODELLER aligned the sequences and generated 100 hDAT
models. The models were evaluated through GA341 and DOPE scoring. The best scoring
model was then uploaded into SybylX 2.1.1, hydrogen atoms were added, and the
structure was minimized using the Tripos Force Field with Gasteiger-Hückel charges. The
finalized hDAT homology model (Figure 27) was then compared to the crystal structure
of dDAT using the biopolymer suite within SybylX 2.1.1. The calculated root mean
squared deviation (RMSD) of all atoms was 2.16 Å. An RMSD < 3 Å for the C atoms of
the backbone of a template and predicted protein is considered a success.82 With all
atoms having an RMSD < 3 Å this hDAT homology model should be considered more
than satisfactory.
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Figure 27. Generated hDAT homology model (cartoon) with labeled transmembrane
(TM) helices.

The generated hDAT homology model was then used to dock methylphenidate (dt9) for
initial homology model docking studies. Methylphenidate (dt9) was first sketched using
SybylX 2.1.1. The sketched molecule was then energy minimized using the Tripos Force
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Field with Gasteiger-Hückel charges. Using GOLD2020, methylphenidate (dt9) was then
used as a test ligand and cocaine (8) was used as a reference ligand in the hDAT
homology model. Methylphenidate (dt9) was docked 100 times and scored with
ChemPLP and GOLD. The best GOLD scoring methylphenidate (dt9) pose formed a salt
bridge interaction with an aspartate residue (D79) (Figure 28). When compared to the
pose of the dDAT crystallized ligand cocaine (8), both phenyl rings as well as the methyl
ester groups had significant overlap for each compound. While the tropane ring of cocaine
(8) and the piperidine ring of methylphenidate (dt9) differ in structure the nitrogen atom
of both compounds was at a distance from D79 for salt bridge formation (i.e., 3.4 and 3.1
Å, respectively).

Figure 28. hDAT homology model (cartoon, green) with possible binding pose of
methylphenidate (dt9, sticks, white) forming salt bridge (dotted line, yellow) with D79.
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All 100 poses generated in GOLD2020 were then subjected to HINT analysis. Using
SybylX 2.1.1 scripting programming language (SPL) each methylphenidate (dt9) pose
was merged with the hDAT homology model. Each formed complex was then minimized
using the Tripos Force Field with Gasteiger-Hückel charges. Using Sybyl 8.1, each
complex had the test ligand removed and HINT analysis was performed. For the initial
partitioning phase, the dictionary method was used for the protein and the calculation
method was used for the ligand.83,84 All other parameters were set to their default values.
The highest HINT score was 868 (Table 11). The pose of the molecule for this high HINT
score also mimicked cocaine with the phenyl ring and methyl ester group overlapping the
same groups of cocaine. The highest contribution to the overall scores was from the
hydrogen bond (HB) formation with the piperidine amine and D79 (3.1 Å). HINT does not
consider salt bridges but a salt bridge can be viewed as a kind of HB.

Table 11. Total HINT score of dt9 solutions with top scores for each type of molecular
interaction.
Scored Solution
Highest

Lowest

Total HINT Score

868

-104

Hydrogen Bond

646

Acid/Base

612

Hydrophobic

789

Polar Clash

-1179
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Aim

2.

Elucidate

factors

determining

the

potency

of

3,4-disubstituted

cathinone/methylphenidate hybrids
a. Synthesis
The synthesis of the target hybrid compounds (119-121) followed the same basic
procedure (Scheme 1). Small differences occurred between the generation of each
compound due to availability of chemicals and attempts to improve yields.

Scheme 1.a General procedure for target compound synthesis.

aReagents

and conditions: a. (Boc)2O, Et3N, MeOH, rt, 1 h; b. N,O-dimethylhydroxylamine

hydrochloride, BOP, Et3N, DCM, rt, 16 h; c. 2.5 M n-BuLi in hexanes, anhydrous Et2O, 78 °C (but, see text), 3 h; d. anhydrous Et2O, -29 °C, 24 h.

The synthesis of compound 119 had been previously accomplished in our laboratory and
proceeded through what is known as a Weinreb ketone synthesis.7 The exact procedure
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was followed for the synthesis of compound 119 with the exception of the starting material
being pipecolic acid (122) and not N-Boc-pipecolic acid (123). For the synthesis of the
Boc-protected intermediate, pipecolic acid (122) was reacted with (Boc)2O in methanol
with Et3N used as a base at room temperature for 1 hour (Scheme 2). This reaction
proceeded by generation of CO2 gas as a side product. Several reaction iterations were
used to produce this intermediate, but this particular setup had the most optimized yields
of all conditions tested at 95%.

Scheme 2.a Synthesis of intermediate 123.

aReagents

and conditions: (Boc)2O, Et3N, MeOH, rt, 1 h.

Following the synthesis of intermediate 123, the next step was to generate the Weinreb
amide 124. This reaction borrows from peptide chemistry and reacts the carboxylic acid
of compound 123 with the amine of N,O-dimethylhydroxylamine hydrochloride in DCM
using the peptide coupling agent (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium
hexafluorophosphate (BOP) and Et3N as a base at room temperature for 16 hours
(Scheme 3). BOP produces the carcinogenic side product hexamethylphosphoramide
(HMPA) during the amide coupling reaction. In future reactions of this nature, it is
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recommended that benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate
(PyBOP) be used as the coupling agent instead of BOP as HMPA is not formed in the
process and the reaction produces the same yields under the same conditions as BOP. 85
The synthesis of intermediate 124 was also repeated several times and the most
optimized setup produced a yield of 85%. The product (i.e., 124) is in most cases reported
as a clear oil. A clear oil was obtained as the final product in this reaction but after several
days it solidified into a white solid with a melting point of 64-66 °C. A method that was
found to enhance the solidification process was to expose the oil to a dry ice/acetone
cooling bath. Upon exposure to the -78 °C temperature cooling bath the oil would solidify
and upon returning to room temperature remained in solid form.

Scheme 3.a Synthesis of intermediate 124.

aReagents

and conditions: N,O-dimethylhydroxylamine hydrochloride, BOP, Et3N, DCM,

rt, 16 h.

An organolithium intermediate (i.e., 128) was then needed for the second portion of the
Weinreb ketone synthesis. The intermediate was synthesized using a lithium halogen
exchange reaction (Scheme 4). 3,4-Dichlorobromobenzene (125) was used as the
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starting material as the bromo substituent was the halogen in the lithium halogen
exchange. Due to the extreme reactivity of organolithium compounds and their sensitivity
to air and moisture the reaction flask was prepped by oven drying and then using three
cycles of gas evacuation by vacuum and back filling with dry N2 gas. Anhydrous Et2O was
added to the flask by syringe followed by the syringe addition of compound 125. Also due
to the sensitivity of organolithium reactions the reaction mixture was cooled to -78 °C
using a dry ice/acetone cooling bath. n-Butyllithium (2.5 M) in hexanes was added via
syringe in a dropwise manner over 15 minutes. This slow addition was to ensure the
reaction did not exceed a safe rate. This reaction was allowed to run over a 3-hour period,
although lithium halogen exchange should occur rapidly. Because organolithium products
are difficult to characterize, intermediate 128 was generated in situ and used directly in
the following reaction for the intermediate 131.

Scheme 4.a Synthesis of intermediate 128.

aReagents

and conditions: 2.5 M n-BuLi in hexanes, anhydrous Et2O, -78 °C, 3 h.

For the synthesis of compound 131 (the N-Boc protected target compound),
intermediates 124 and 128 were reacted with each other in Et2O (Scheme 5). Compound
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124 was placed in an oven-dried flask after which was evacuated by vacuum and back
filled with N2 gas three times. Afterwards, anhydrous Et2O was added via syringe and the
reaction mixture was cooled to -29 °C using a dry ice/o-xylene cooling bath. Once the
reaction mixture was cooled, intermediate 128 was added via syringe in a dropwise
manner over a 15-minute period. This slow addition time was taken to add the
organolithium intermediate in order to avoid rapid exotherms. This reaction was allowed
to run overnight as the Weinreb ketone reaction intermediate formed is somewhat stable.
A reverse quenching method was employed to reduce any side product formation by
slowly adding portions of the reaction mixture to a cold 1 M KH2PO4 solution.

Scheme 5.a Synthesis of intermediate compound 131.

aReagents

and conditions: anhydrous Et2O, -29 °C, 24 h, 1 M KH2PO4 reverse quench.

In order to generate the final target compound 119, intermediate 131 was deprotected
and the freebase of 119 was converted to an HCl salt (Scheme 6). Deprotection and salt
formation was accomplished in one pot by first dissolving 131 in anhydrous methanol and
cooling the solution with an ice bath. Then, methanolic HCl was added in a dropwise
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manner to the reaction mixture until the pH of the solution was near 1. The reaction
mixture was allowed to stir overnight. Upon removal of solvent, washing with acetone,
and recrystallizing using anhydrous methanol, pure target product 119 was collected with
a melting point of 272-273 °C. This melting point corresponds to what was previously
recorded at 273-275 °C.7 For full characterization of the target compound 119 nuclear
magnetic resonance (NMR) spectrometry, high resolution mass spectrometry (HRMS),
and C, H, N analysis were utilized and each analysis method confirmed successful
synthesis and purity (Figure 29). C, H, N analysis had not previously been reported for
compound 119.

Figure 29. 1H NMR spectrum of compound 119.
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Scheme 6.a Synthesis of target compound 119.

aReagents

and conditions: methanolic HCl, anhydrous methanol, 0 °C, 24 h.

After the success of the first target compound (i.e., 119), synthesis of compound 120 was
attempted. Four attempts were made to finally generate compound 120. The first attempt
proved to be successful albeit having immensely low yields. The amount of compound
120 obtained was just enough for characterization but not enough for future biological
assay studies. The second attempt made use of a newer batch of the starting material 4bromo-o-xylene (126) in an effort to increase yields. This was in case the starting material
had decomposed or been compromised. The second attempt yielded a higher total
amount of a white crystalline solid than the first. The thin layer chromatography (TLC) for
this second compound produced the same retention factor (Rf) value as the first attempt.
Even the CombiFlash Companion/TS readout produced a similar chromatogram as the
first attempt. Unfortunately, when it came to the melting point it was close to 100 °C less
than for the characterized first compound (i.e., 120). Also, 1H NMR characterization
showed that compound 120 was not present in the test sample. Attempt two was a failure
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(Scheme 7). Further characterization was not carried out and another set of reactions
was set up for the third attempt.

Scheme 7.a Failed synthesis of target compound 120.

aReagents

and conditions: a. 2.5 M n-BuLi in hexanes, anhydrous Et2O, -78 °C, 3 h; b.

anhydrous Et2O, -29 °C, 24 h.

For the third attempt, the original batch of 4-bromo-o-xylene was used as it was the one
that produced a successful synthesis and the only variable changed between the first two
attempts. Again, a white crystalline solid was isolated with similar Rf and chromatogram
to compound 120, but it had a much lower melting point. This time several
recrystallizations using absolute ethanol were attempted to further purify the white solid
and possibly raise the melting point and produce a clean 1H NMR spectrum. The melting
point stabilized at around 160 °C, compared to 263-264 °C for the original sample of 120.
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The 1H NMR integrated for the number of protons that was expected for compound 120,
but the anticipated aromatic signals were missing and instead only aliphatic protons were
observed (other than the proton signals from the protonated amine) (Figure 30). On
further analysis it was hypothesized that the product formed was 132 (Scheme 8). This
was confirmed through HRMS generating a signal within 5 ppm of the theoretical
compound (i.e., 132). A search of the literature did not yield any articles describing
compound 132.

Figure 30. 1H NMR spectrum of compound 132.
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Scheme 8.a Synthesis of off-target compound 132.

aReagents

and conditions: 2.5 M n-BuLi in hexanes, anhydrous Et2O, -29 °C, 24 h.

After the identification of compound 132 it was established that the lithium halogen
exchange reaction was not proceeding. Possible explanations for this reaction not taking
place could be due to an improper amount of n-BuLi reacting either from an inaccurate
titer from the reagent bottle due to degradation or moisture/air exposure to the reaction.
This explanation was dismissed because compound 132 would not be able to form if this
was the case. Another option would be to use t-BuLi for the lithium halogen exchange
because it is an irreversible reaction but none was available at the time. Regardless, the
lithium halogen exchange reaction should be rapid and take place for n-BuLi and reagent
126. For the fourth and final attempt to produce target product 120 the lithium halogen
exchange set up and reaction was meticulously monitored. Upon cooling the 4-bromo-oxylene (126)/anhydrous Et2O solution to -78 °C with a dry ice/acetone bath it was noted
that a small amount of white solid was present in the flask. Testing this observation, a
small vial was filled with a large amount of reagent 126 and anhydrous Et2O and
submerged into the cooling bath. Solid 4-bromo-o-xylene (126) instantly precipitated from
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solution. It would seem that the reagent was insoluble at this temperature and not taking
part in the lithium halogen exchange reaction. A literature search revealed that 4-bromoo-xylene (126) melting point is -0.2 °C.86 The next step was to determine if organolithium
reactions can safely be run at higher reaction temperatures near 0 °C and a literature
search was successful in answering that question.87 In a study on the effects of solvent
on lithium-bromine exchange of aryl bromides using n-BuLi at 0 °C, it was clearly shown
that the lithium halogen exchange could safely take place with good yields at higher
temperatures than -78 °C.87 With this knowledge the fourth attempt was continued at 0
°C but using the same molar equivalent of n-BuLi as was used in the study by Bailey et
al.87 (Scheme 9).

Scheme 9.a Successful synthesis of target compound 120.

aReagents

and conditions: a. 2.5 M n-BuLi in hexanes (1.2 equiv.), anhydrous Et2O, 0

°C, 3 h; b. anhydrous Et2O, -29 °C, 24 h.
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After quenching, extraction, and purification a white crystalline solid was obtained. Just
as in the first attempt, this compound had the same Rf and chromatogram profile for
compound 120. The melting point was 262-264 °C matching the previously fully
characterized target compound 120. The 1H NMR spectra displayed the anticipated
proton signals in the aromatic region that were missing in the previous two attempts and
integrated for the correct total number of protons (Figure 31). HRMS also confirmed the
desired mass within 5 ppm. Target compound 120 was successfully synthesized and had
the highest yield (27%) of this hybrid cathinone/methylphenidate series.
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Figure 31. 1H NMR spectrum of compound 120.

The synthesis of target compound 121 followed the same procedures for the synthesis of
compound 119 with the only difference in using 2-bromonaphthalene (127) instead of 3,4dichlorobromobenzene (125). This compound had a high melting point (245-247 °C)
similar to the other two target products. 1H NMR, HRMS, and Fourier-transform infrared
spectroscopy (FTIR) were used to characterize compound 121 (Figure 32). FTIR was
able to demonstrate the band from the target product’s ketone functional group at 1674
cm-1.
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Figure 32. 1H NMR spectrum of compound 121.

b. Biological Studies
Once each compound had been successfully synthesized and fully characterized their
ability to inhibit DAT was examined using biological assays. The hyrbid compound
backbone and several analogues had been previously shown to be DAT reuptake
inhibitors and not releasing agents using a Ca2+ fluorescence assay.7 The compounds
were evaluated as DAT reuptake inhibitors using an APP+ uptake assay. The assay was
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performed on HEK Flp-In T-REx 293 cells stably expressing hDAT. Fluorescence
microscopy was used to measure fluorescent intensity of the cells. APP+, which is a DAT
substrate, fluoresces at an emission wave length of 540 nm with an excitation of 460 nm
after transporter mediated transport intracellularly. A stepwise loss in fluroescent intensity
is seen when the APP+ substrate is added with increasing concentrations of agents that
interact with DAT. The potency of the test agent is in direct proportion to the inhibition of
the fluorescence from APP+. Methylphenidate t9 and compound 119 were both used as
standards in testing. Dose response curves (Figure 33) were obtained for the two
standards and compounds 120 and 121 using six different concentrations (1 nM, 10 nM,
30 nM, 100 nM, 300 nM, and 1 M) . Each concentration was repeated in triplicate and
each experiment was repeated on separate days in order to reduce error. All data were
analyzed using EasyRatioPro 3 and then plotted with GraphPad Prism 8.0.1. For each
experiment 40 separate cells that showed activity were choosen as regions of interest
(ROI). These ROIs were then used for the data to build the IC 50 inhibition curves (Figure
33). Each data set was background subtracted and normalized by the average positive
control for the experiment day. To fill out some of the curves more completely lower and
higher concentrations of the test compounds were used. For both compounds 119 and
121 an extra set of experiments were performed to include concentrations of 0.1 nM and
3 M. For compound 120 an extra experiment was performed at 3 M.
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Figure 33. Dose-response curves of t9 and hybrid compounds 119-121 in an APP+
uptake assay at hDAT.

The IC50 value of each compound is shown in Table 12. The potency of the standard
methylphenidate (t9, IC50 = 70 ± 16 nM ) was similar to what had been reported previously
(IC50 = 72 nM).7 The hybrid compound 119 was about twice as potent (IC50 = 17 ± 2.34
nM) than previously reported (IC50 = 47).
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Table 12. Uptake inhibition (IC50, nM) values of methylphenidate (t9) and hybrid
compounds 119-121 in the APP+ uptake assay at hDAT.
Compound

IC50 ± SEM (nM)

t9*

72

t9

70 ± 16

119*

47

119

17 ± 2.34

120

379 ± 88

121

50 ± 25

*As reported previously.7

What can be seen with the new data is that all compounds are much more potent
compared to the unsubstituted parent compound 112 (IC50 = 1080 nM).7 The dimethyl
compound 120 was weaker (IC50 = 379 ± 88 nM) than the other two test compounds. This
result shows that the potency of these disubstituted benzoylpiperidines is not strictly
related to lipophilicity or occupancy of the chemical space in the binding pocket of hDAT
but these two factors likely contribute to greater potency. The naphthyl compound 121
with an IC50 = 50 ± 25 nM was more potent than the methylphenidate standard and had
a similar potency to the previously published data for compound 119. The similarity in
these two compounds’ (i.e, 119, 121) potencies demonstrate that the electron
withdrawing character of these substituents is likely the cause for an even greater
increase in potency from the parent compound 112 and the electron donating dimethyl
compound 120. Also due to the high potency of compound 121 it is unlikely that
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compound 119 is participating in halogen bonding interactions or if these interactions are
present, they contribute minimally to its overall increased potency. However, both 119
and 121 analogs could participate in hydrogen bond interactions via either the chloro
substituents of compound 119 or the aromatic hydrogen atoms of compound 121. It is not
possible with this data to state whether or not the potency of these two compounds is due
to their electron withdrawing properties, hydrogen bonding capabilities, or a combination
of both. To be certain of these interactions modeling and future compounds will have to
be explored. These data correlate with the modeling data as in both instances the
dimethyl compound 120 was the lowest scoring for modeling (see “c. Docking Studies”
section) and had the weakest activity in the APP+ assay (see below). Compound 121 has
a previously studied corresponding methylphenidate analog 78 with a pIC50 = 7.96. Using
the previously developed plot of the hybrid analogs and the corresponding
methylphenidate compounds it would be predicted that compound 121 should have a
pIC50 = 6.60 or about 250 nM (Figure 34). The experimental pIC50 for compound 121 was
0.7 log units greater with a potency approximately five times greater than that of the
prediction.
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Figure 34. Correlation between the binding data of t9 analogs (x-axis) and APP+ uptake
assay data (y-axis) for the corresponding methylphenidate hybrid compounds (r = 0.91,
n = 8). Predicted pIC50 activity for compound 121 analog (red).

Adding the experimental compound 121 data point to previously plotted correlation data
increases the number of corresponding compounds to n = 9 (Figure 35). The r value
lowers to 0.89 from 0.93 but the correlation is still statistically significant. Using this new
plot the predicted corresponding dimethyl methylphenidate compound to the hybrid 120,
which has not been reported, should have a binding pIC 50 of approximately 7.57 (Figure
35). What is still undetermined from these experiments are the relative potencies between
the two possible isomers of each compound and there is still not enough data for
disubstituted benzoylpiperidines for statistical significance. Several compounds will still
need to be explored for an n = 6. At that point individual factors involved with the structural
variation between the analogs can be correlated.
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Figure 35. Correlation between the binding data of t9 analogs (x-axis) and APP+ uptake
assay data (y-axis) for the corresponding methylphenidate hybrid compounds (r = 0.89,
n = 9). Predicted pIC50 binding for dimethyl t9 analog (red).

c. Docking Studies
Both S and R isomers of the three compounds 119, 120, and 121 were sketched in SybylX
2.1.1 and energy minimized using the Tripos Force Field with Gasteiger-Hückel charges.
Using Gold2020 each compound was docked 100 times in the hDAT homology model
with cocaine as a reference ligand. All poses were scored with GOLD and ChemPLP.
Gold scores for each of the isomers of the three compounds were within 1 unit of each
other suggesting both isomers bind at the S1 central binding site of hDAT. The highest
scoring pose for each compound were in a similar pose and had a high degree of overlap
(Figure 36). There was not an observed difference in the rotomer orientation of D79 for
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any of the compounds tested. Each of the S isomers was within hydrogen bond distance
from the D79 (i.e., 2.56, 2.55, and 2.59 Å for 119, 120, and 121, respectively) while the R
isomers were about half an angstrom too far for the desired interaction. These distances
and scoring suggest that the S isomers of the three compounds might be more potent
than their R isomer counterparts.

Figure 36. hDAT homology model (cartoon, green) with possible binding poses of S
isomer hybrids 119 (sticks, purple), 120 (sticks, cyan), and 121 (sticks, magenta).

All poses generated were analyzed through HINT. Using SybylX 2.1.1 scripting language
each pose of both S and R isomers of hybrid compounds 119, 120, and 121 was merged
with the hDAT homology model. Each formed complex was then minimized using the
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Tripos Force Field with Gasteiger-Hückel charges. Using Sybyl 8.1, each complex had
the test ligand extracted into its own molecular area and HINT analysis was performed.
For the initial partitioning phase, the dictionary method was used for the protein and the
calculation method was used for the ligand.83,84 All other parameters were set to their
default values. The highest scoring compound in HINT was the S isomer of hybrid 121
(Table 13). While compound 121 was not the most potent of the series there is a good
relationship between its high HINT score and potency. The other two compounds (i.e.,
119 and 120) had similar scores to previously docked methylphenidate (dt9). Both S and
R isomers scored well with the S isomer of each compound scoring higher than the
corresponding R isomer. These results suggest that all compounds are likely (and, in fact,
were) active and that the S isomer, which has slightly better interactions within the S1
central binding site of hDAT, is probably more potent than the R isomers. While synthesis
and biological studies only examined the racemates of compounds 119-121, The same
docking results could be used in future studies if the isomers are to be isolated.

Table 13. HINT scores in descending order of compounds 119-121 and dt9.
Compound

HINT score

S 121

1040

R 121

904

dt9

868

S 119

842

S 120

834

83

R 119

809

R 120

743

The HINT and GOLD scores do not reveal the relative potencies of the compounds. It has
already been established that compound 119 is more potent than dt9 yet for this modeling
study 119 scored lower for both isomers than dt9. For the potential halogen bonding
aspect of compound 119 HINT and GOLD cannot answer this question because neither
software takes this particular interaction into account. This could be a reason why
compound 119 is scored lower than dt9. If a halogen bond interaction could be scored
for either of these software packages then 119 might have the highest score. Hydrogen
bond interactions with the substituents were not observed in the HINT analysis tables for
compounds 119 or 121. By default, an aryl hydrogen’s partial positive charge (such as
the aryl hydrogens on compound 121) is not considered in HINT. S149 in particular is
aligned in such a way that the oxygen atom lone pair is in direct alignment of compound
119’s 3-chloro substituent’s terminal end where a sigma hole would occur as well as one
of compound 121’s aryl hydrogens from the extended phenyl ring. These atoms are within
a distance of 3.5 Å and 3.22 Å for compounds 119 and 121, respectively. Compound
121’s planar hydrogen atom from the extended aryl ring with its partial positive charge
could be involved in electrostatic interactions at this distance from S149’s oxygen atom.
There is tolerance for the large naphthyl ring mainly due to the space G153 and S149
allows in a similar manner that is seen with the methylenedioxy ring of MDPV (10; See
Project 2). The lowest scoring compound was compound 120. It is likely that the three
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test compounds (119-121) scored somewhat similarly due to the hydrophobic nature of
the substituents. Possible differences could then be due to the electron withdrawing
character of the substituents of 119 and 121. This could be a reason why compound 121
had the highest HINT score. The scores are too close in magnitude to make definitive
conclusions about potency though. What these data can contribute is that all of these
compounds more than likely should (and, in fact, did) interact with hDAT. The modeling
allows for speculation of the actual configuration that these disubstituted compounds
(119-121) take although it will not be proved unless either a constricted analog is
developed that shows similar activity to the parent compounds or a crystal structure with
one of these compounds is solved. Most likely though the structure’s substituents
probably take the same orientations of the previous solved crystal structures of DA and
3,4-dichlorophenethylamine in dDAT. All compounds in the modeling were likely to be
active and the previous biological data corroborates that finding.

85

B. Project 2.
Aim. Evaluate binding modes of selected cathinones at DAT mutant transporters
utilizing 3D molecular modeling
dDAT which can be considered a natural mutant of hDAT displays unique properties for
certain inhibitor psychostimulants. MDPV (10), -PVP (11), and MDPPP (39) have all
been identified on the clandestine market as drugs of abuse. These three
psychostimulants are potent hDAT inhibitors but show virtually no activity at dDAT
(unpublished findings). With this distinction between the two species of DATs, gain-offunction experiments were performed upon where mutating one non-conserved amino
acid residue at a time from dDAT to hDAT, might restore activity to the three stimulants
to what is observed in hDAT. The amino acid residues chosen for mutation were
A117S/D121G/P323V/F318C. Three of the amino acid residues that were chosen (i.e.,
A117, P323, and F318) were those that dDAT and hSERT have conserved but are not
present in hDAT (Figure 37). These residues are either part of, or part of the opening to,
the S1 central binding site in dDAT and hSERT crystal structures.4,15 All three stimulants
show no activity towards hSERT and these residues might be responsible for that lack of
activity. The other amino acid residue D121 that was mutated was one that is unique to
dDAT only and has been shown previously to be important for DAT inhibitor agent
activity.15 Although several different mutants were constructed, only a triple mutant
(A117S/D121G/P323V) and quadruple mutant (A117S/D121G/P323V/F318C) are
considered here. The potencies of 10, 11, and 39 at these two mutants, as well as at wildtype dDAT and hDAT are shown in Table 13 (Dr. Eltit; unpublished data).
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Figure 37. Sequence and alignment of hSERT, dDAT, and hDAT. Highlighted areas form
the S1 central binding site and boxed amino acids are selected sites of dDAT mutations.
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The largest increase in potency restoration contained all four-point mutations (Table 14).
This is impressive because only four mutations were needed to see great improvement
in functional activity. The functional data shows that the mutation of the four nonconserved residues from hDAT into dDAT restored activity of MDPV (10) by just over 100fold compared to wt dDAT (Table 14; Dr. Eltit; unpublished data). Modeling studies were
then used to compare the transporter structures and determine what molecular
interactions were taking place between the ligands and transporters.

Table 14. Potency of MDPV (10), -PVP (11), and MDPPP (39) inhibiting DA-induced
Ca2+ signals at the indicated transporters.a
Construct, pIC50 ± SEM (M), (IC50 nM; # cells analyzed)
wt dDAT

triple dDAT mut

quad dDAT mut

wt hDAT

4.56 ± 0.02

5.92 ± 0.02

6.60 ± 0.04

7.47 ± 0.01

(27,350; 437)

(1,207; 438)

(251; 396)

(34; 459)

4.68 ± 0.03

5.82 ± 0.03

5.96 ± 0.03

7.29 ± 0.01

(20,710; 699)

(1,531; 599)

(1,094; 481)

(51; 569)

Inactive

4.80 ± 0.02

4.89 ± 0.01

5.47 ± 0.02

(>>30,000; 246)

(16,960; 551)

(12,950; 507)

(3,418; 639)

MDPV

-PVP

MDPPP

aUnpublished

data from Dr. Eltit’s lab.
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Of all the different combinations of dDAT mutants, the four-point mutation (i.e., the
quadruple mutant) saw the largest restoration of activity and was used for the subsequent
modeling studies. The models used for the molecular modeling studies were the Project
1 hDAT homology models, the available dDAT crystal structure PDB ID: 4XP4 for wt
dDAT, and the same dDAT crystal structure as template to generate a 3D homology
model of the quadruple (A117S/D121G/P323V/F318C) dDAT mutant. The three models
were energy minimized using Tripos Force Field with Gasteiger-Hückel charges then
compared using the Biopolymer suite within SybylX 2.1.1. The overall structure of these
energy-minimized models was similar; the RMSD was 2.02 Å between hDAT and the
quadruple dDAT mutant homology models, and 2.16 Å between hDAT and the wt dDAT
structures. As expected, wt dDAT and the quadruple dDAT mutant models were very
similar (RMSD = 0.29 Å). When the S1 central binding pockets were compared, the
RMSD between hDAT and the quadruple dDAT mutant is 2.11 Å, and between hDAT and
wt dDAT models, it was 2.12 Å. The RMSD of the binding pockets of the wt dDAT and
quadruple dDAT mutant models was 0.36 Å. The total volume of the pockets increased
from 2425 Å3 for wt dDAT, to 2533 Å3 for the dDAT mutant, to 3170 Å3 for hDAT. Two of
the mutations contained residues (P323V/F318C) that were not part of the S1 central
binding site. For docking studies this is a difficult undertaking as the test ligand is placed
within the defined binding site to start. In reality, these mutations (P323V/F318C) might
affect activity due to their location on the transmembrane helices and influence entry into
the S1 site. Figure 38 shows the opening to the S1 site from the extracellular space for
the transporter.
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Figure 38. hDAT homology model (Connolly surface, green) with MDPV (10, sticks,
yellow) in the S1 central binding pocket (Connolly surface, red).

The S1 site is comprised of the central portions of the transmembrane helices TM1, TM3,
TM6, and TM8.16 Helices TM3 and TM8 are uninterrupted but, helices TM1 and TM6 are
subdivided into two helices (1a and 1b, and 6a and 6b, respectively) connected by a nonhelical segment in the middle.16 F318 and P323 are part of TM6 but they do not directly
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face ligands. F318 is adjacent to the highly conserved F319 in the TM6a helix. F319 is
considered the extracellular gate controlling access to the central cavity from the
extracellular entrance.88 This gate is “open” in the outward facing conformation, and F319
rotates to a “closed” conformation in the occluded state of the transporter. 15 The F318C
P323V mutations might influence F319 operation in such a way that it allows better access
of the bulky MDPV molecule to the S1 site in the outward facing state through increased
structural flexibility and manipulation of F319 positioning, this positive effect of F318C is
less evident for the smaller -PVP (11) and MDPPP (39) molecules.

For the other two mutations (A117S/D121G) that lie within the S1 binding pocket, docking
studies were conducted to better understand potential molecular interactions with MDPV
(10), -PVP (11), and MDPPP (39) within the three transporters. GOLD2020 was used to
generate 100 docking solution poses of each agent in each DAT model totaling for 900
generated poses. The S1 binding site has a composition that can be divided into three
subsites or subpockets (A, B, and C; Figure 39) that are occupied by the terminal amine,
aryl portion, and  side chain, respectively.15 Table 15 shows the amino acid residues
that constitute the S1 central binding site for each of the three transporters.
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Figure 39. Divided A, B, and C subpockets with possible binding pose of MDPV (10,
sticks, yellow), -PVP (11, sticks, orange), and MDPPP (39, sticks, wheat) in hDAT (lines
and cartoon, cyan) S1 central binding site.

HINT analysis was used to investigate the interactions between the aromatic and alkyl
side chains of the compounds and subpockets A, B, and C of the dDAT and hDAT
models.84 The amino acids displayed in Table 15 were identified using the HINT analysis.
For the initial partitioning phase, the dictionary method was used for the proteins and the
calculation method was used for the ligands.83,84 All other parameters were set to their
default values. In the highest scoring HINT ligand-protein complex solutions, the agents
showed the same orientation at all three transporters (Figure 39). These poses embody
the same 3-dimensional space in the three subpockets with the same characteristics (i.e.,
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aromatic ring, protonated nitrogen atom, and alkyl side chain) as the solved crystal
structure pose of cocaine bound to dDAT (PDB ID: 4XP4).

Table 15. Amino acid residues corresponding to the A, B, and C subpockets that make
up the S1 central binding site in wt dDAT, dDAT (i.e., quadruple) mutant, and hDAT.
Subpocket

wt dDAT

dDAT mutant

hDAT

A

F43, A44, D46,

F43, A44, D46,

F76, A77, D79,

A48, Y124, F319,

A48, Y124, F319,

A81, Y156, F320,

L321, G322, S421

L321, G322, S421

L322, G323, S422

A117, V120, D121,

S117, V120, G121,

S149, V152, G153,

S421, S422, G425,

S421, S422, G425,

S422, A423, G426,

I429, Y455, S426,

I429, Y455, S426,

V430, T456, M427,

N125

N125

N157

D46, V120, F319,

D46, V120, F319,

D79, V152, F320,

F325, D475, A479,

F325, D475, A479,

F326, D476, A480,

I483, Y123

I483, Y123

I484, F155

B

C

HINT scores showed low scores for MDPPP (39) in all models, whereas MDPV (10) and
-PVP (11) showed much higher scores at hDAT (Table 16).
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Table 16. Gold and HINT scores for docking solutions of the agents MDPV (10), α-PVP
(11), and MDPPP (39) in the wt dDAT, dDAT mutant, and hDAT models.
Agent

Transporter

Gold score

HINT score

MDPV

wt dDAT

58.08

376

MDPPP

wt dDAT

54.49

186

-PVP

wt dDAT

51.91

605

MDPV

dDAT mutant

58.89

261

MDPPP

dDAT mutant

54.03

342

-PVP

dDAT mutant

53.30

463

MDPV

hDAT

55.32

727

MDPPP

hDAT

52.13

287

-PVP

hDAT

51.25

759

Each individual Interaction involving the atoms within subpockets A, B, and C with the
three test compounds were extracted from the resulting HINT table and tabulated (Table
17). The number of positive and negative interactions between a docked molecule at each
protein model showed that the total favorable interactions were highest at hDAT and the
more unfavorable interactions were highest at wt dDAT for each agent. These results are
consistent with the functional data (Table 14). A description of the potential interaction of
MDPV and its analogs at each subpocket (A, B, and C; Figure 39) is provided below.
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Table 17. Tabulated positive, negative, and sum total HINT interactions of docked
solutions for the agents MDPV (10), -PVP (11), and MDPPP (39) in the wt dDAT, dDAT
(i.e., quadruple) mutant, and hDAT models.
Agent

Transporter

Positive

Negative

Sum Total

Interactions

Interactions

MDPV

wt dDAT

8

-12

-4

MDPV

dDAT mutant

8

-9

-1

MDPV

hDAT

11

-8

3

-PVP

wt dDAT

8

-8

0

-PVP

dDAT mutant

7

-7

0

-PVP

hDAT

11

-6

5

MDPPP

wt dDAT

6

-10

-4

MDPPP

dDAT mutant

6

-8

-2

MDPPP

hDAT

11

-4

7

a. Interactions at subpocket A
MDPV (10), -PVP (11), and MDPPP (39) all have the same structural feature (the
pyrrolidine ring) occupying subpocket A (Figure 40). Subpocket A had the highest scoring
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HINT interactions compared to the other subpockets. The cause for this high score is
driven by the salt bridge formed by the essential amino acid residue D46 (dDAT)/ D79
(hDAT) and the protonated pyrrolidine nitrogen atom.

Figure 40. Amino acid residues (lines) that make up subpocket A for hDAT (cyan), dDAT
mutant (green), and wt dDAT (purple). MDPV (10, sticks, yellow) shown as a reference.

b. Interactions at subpocket B
The aromatic portion (i.e., benzodioxole or phenyl ring) of the three agents was located
within subpocket B of the transporters (Figure 41). -PVP (11) differs from the other two
agents in the aromatic portion of the molecules in that it lacks the methylenedioxy ring
found in MDPV (10) and MDPPP (39). It has previously been shown that this difference
has little effect on the potency of 11 when compared to MDPV (10) in hDAT.39 The
influence of this methylenedioxy ring section in wt dDAT and dDAT mutant should be
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apparent if there is a large difference between the HINT scores of -PVP (11) and the
other two agents. Its scores were higher for all three models. This is contrary to the mutant
transporter biological data but is likely due to fewer clashing interactions from the smaller
phenyl ring compared to the benzodioxole ring in the modeling.

Figure 41. Amino acid residues (lines) that make up subpocket B for hDAT (cyan), dDAT
mutant (green), and wt dDAT (purple). MDPV (10, sticks, yellow) shown as a reference.

hDAT had the most favorable interactions with the compounds at residues V152, S422,
A423, G426, and M427. wt dDAT showed favorable interactions with residues V120,
G425, I429. Two of the mutations, A117S and D121G, make up a portion of subpocket B
and correspond to residues S149 and G153 in hDAT. These two residues have a direct
effect on ligand/protein interactions at the S1 central binding site. The D121G dDAT single
mutant also was the most effective at increasing MDPV’s (10) potency in the biological
assays compared to any other dDAT single mutant evaluated (data not shown). The major
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clashes observed in subpocket B were between the docked agents’ aryl portions and the
residues A117 and D121 in wt dDAT. These interactions are more favorable with the
related residues S149 and G153 in hDAT. The dDAT mutant, having the D121G mutation,
exchanges the negative clash of the bulky aspartate residue to a positive interaction with
the smaller neutral glycine. This allows more space for the ligand to orient and removes
polar clashing interactions such as electronegative repulsion from the oxygen atoms of
the methylenedioxy ring of MDPV (10) and the oxygen atoms of D121. The A117S
mutation favors interactions with the agents by possible hydrogen bonding with one of the
oxygen atoms of the methylenedioxy ring for MDPV (10)/MDPPP (39) and/or by bonding
with the protein backbone, thereby increasing the size of the pocket. The measured
distance of the potential hydrogen bond between the two methylenedioxy ring containing
agents and the dDAT mutant and hDAT models was 3.9 Å and 7.53 Å, respectively. These
distances make this interaction unlikely and just a weak electrostatic interaction if
anything. If the weak but favorable interaction is occurring it would explain why that in all
the biological data, -PVP (11) (without the methylendioxy ring) was slightly weaker than
MDPV (10) except for the wt dDAT, which has alanine and not serine at that position. It
was found that S117/S149 was able to form a hydrogen bond with the backbone amide
oxygen atom of F325 or F326 in the dDAT mutant and hDAT models, respectively. The
measured distances of these possible hydrogen bonds are 2.6 Å and 2.8 Å for the dDAT
mutant and hDAT, respectively. The possible S117 and F325/F326 hydrogen bond would
pull the S117/S149 residue away from the binding pocket creating more space for the
ligand to bind. This hydrogen bond interaction cannot take place with an alanine residue
and would explain the clashes in the wt dDAT model. The dDAT mutant did have a
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negative interaction at G425 with the aryl portion of the agents compared to wt dDAT
where this interaction was not observed.

c. Interactions at subpocket C
Subpocket C is enveloped with hydrophobic amino acid residues (Figure 42). The only
nonneutral residues are the two aspartates D476/D475 and D79/D46 for hDAT and
dDATs, respectively. The hydrophobic alkyl side chains, methyl for MDPPP (39) and npropyl for MDPV (10) and -PVP (11), occupied subpocket C with nothing but favorable
hydrophobic interactions. In fact, the methyl substituent of MDPPP (39) did not have any
overall negative interactions, only fewer favorable interactions within subpocket C
compared to the other two compounds. In the hDAT model the α-methyl substituent of
MDPPP (39) is not long enough to interact with residues (I484 and F155), or residues
(I483 and A479) in the mutant and wt dDAT models, respectively. The absence of these
interactions is most likely the driving force for why MDPPP (39) is much less potent
compared to the other two agents MDPV (10) and -PVP (11). Due to only favorable
interactions within subpocket C for both hDAT and dDATs, the difference in potency
between the different transporters for MDPV (10) is plausibly not driven by its alkyl side
chain. That is to say an extended alkyl side chain most likely benefits potency of these
agents in DAT regardless of the construct (i.e., dDAT or hDAT) and is not responsible for
the gain in potency observed.
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Figure 42. Amino acid residues (lines) that make up subpocket C for hDAT (cyan),
dDAT mutant (green), and wt dDAT (purple). MDPV (10, sticks, yellow) shown as a
reference.
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V. Conclusions
A two-pronged approach has provided a means in which to expand the understanding of
DAT SAR using new compounds and “known” transporters as well as “known”
compounds and new (i.e., mutant DAT) transporters. Through this work new hDAT
homology models were generated, and new potent DAT inhibitors were synthesized,
characterized, and evaluated. These projects provided insight on the types of molecular
interactions involved in hDAT function and small molecule inhibitors for aryl substituents

For project 1 a new homology model of hDAT was generated that was able to successfully
determine that the new hybrid compounds would be active. It was found that all
compounds tested were active in the nanomolar range exhibiting that lipophilicity () plays
a role in DAT activity. Differences in magnitude of activity could be attributed to electronic
character ( value) favoring electron withdrawing substituents as 3,4-dichloro compound
119 and naphthyl compound 121 were more potent than 3,4-dimethyl compound 120.
The volume of all the substituents are tolerated but are not the cause of difference in
activity as compound 121 was similar in potency compared to the smaller compound 119.
Both compounds 119 and 121 can be hydrogen bond acceptors while compound 120
cannot. Compound 119 forming a halogen bond is not likely because 121 is almost as
potent.

For project 2 using modeling it was found that residues S149, V152, G426, and M427
were identified to be vital interactions within the S1 central binding site. Non-conserved
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residues identified can drive MDPV (10) selectivity not solely by stabilizing binding, but
also controlling access to its binding site. The mutations on the outside of the binding site
at the entrance can lend flexibility to the transporter and the overall size of the central
binding pocket can greatly affect an agent’s activity.

Modeling in both projects helped identify amino acids that are important for DAT activity
through both SAR of small molecules and DAT mutants. Although attempts were made
to understand the functional activity/potency of benzoylpiperdines via use of molecular
modeling studies, it might be noted that use of radioligand binding data might have
provided an even better picture of ligand-transporter interactions. Nevertheless, the
current approach can be justified because the potency of methylphenidate (9) analogs as
DAT reuptake inhibitors has been demonstrated to be significantly correlated with their
DAT affinity as determined using radioligand binding.7

Future work should include synthesis and evaluation of more disubstituted
benzoylpiperdines as well as optical isomers to round out the SAR for the aryl portion of
DAT inhibitors. Also, in vivo studies should be conducted to see if these compounds have
any abuse liability or can be used for therapeutics in the treatment of dopamine
dysregulation.
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VI. Experimental
A. Molecular Modeling
One hundred homology models of hDAT were generated using MODELLER 9.24 and
three crystal structures as a template.89,90 The two highest identity dDAT crystal structures
(PDB ID: 4XPB, 4XPT) at 55.35% and 55.33% identity, respectively, as well as the
greatest query coverage hSERT crystal structure (PDB ID: 6VRH) at 92% coverage were
used.15,18,90 The alignment of the structures was conducted using BLAST.81 The
sequences of both dDATs, hSERT, and hDAT were obtained from GenPept (accession
codes 4XPB_A, 4XPT_A, 6VRH_A, and BAA22511, respectively). Due to the lack of
corresponding residues, the first 54 residues from the N-terminus were not modelled. The
homology model with the lowest discrete optimized protein energy (DOPE) score and
highest GA341 score was then used for docking.89,91 GA341 is a multivariate scoring
function that depends on compactness and combined statistical potential z-score of the
model as well as the percentage sequence identity of the target-template alignment that
was used to build the model.89,91 The mutant quadruple transporter in the present study
was generated using SybylX 2.1.1 (TRIPOS Associates, Inc) by replacing the dDAT (PDB
ID: 4XP4) amino acids with the corresponding hDAT amino acids D121G, P323V, A117S,
and F318C.15,92 The compounds MDPV, -PVP, and MDPPP (as their S isomers) were
sketched using SybylX 2.1.1 and energy minimized using the Tripos Force Field with
Gasteiger-Hückel charges. The automated docking program GOLDsuite2020 was used
to dock the three compounds one hundred times in each of the three DAT models (wt
dDAT, quadruple dDAT mutant, hDAT) using D46 and D79 residues and the surrounding
10-Å radius to define the binding pocket for the dDAT and hDAT models, respectively. 93
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All solutions generated from GOLD were then merged with their respective protein and
energy-minimized using the Tripos Force Field with Gasteiger-Hückel charges in SybylX
2.1.1.93,83 The Hydropathic INTeraction (HINT) analysis software within SYBYL 8.1 was
used to quantify the nature and magnitude of the molecular interactions between the
aromatic and alkyl side chains of the compounds and subpockets A, B, and C of the dDAT
and hDAT models.84 For the initial partitioning phase, the dictionary method was used for
the protein and the calculation method was used for the ligands. 83,84 All other parameters
were set to their default values. Atom-based interactions involving atoms within
subpockets A, B, and C were extracted from the resulting HINT table and tabulated.
MOLCAD and BioPolymer suite within SybylX 2.1.1 were used for binding pocket volume
calculations and RMSD calculations, respectively.

B. Synthesis
Melting points were taken on MEL TEMP melting point apparatus in glass capillary tubes
and are uncorrected. 1H NMR spectra were recorded using a Bruker AXR 400 MHz
spectrometer with tetramethylsilane (TMS) as an internal standard. Signal positions are
given in parts per million (δ) downfield from TMS, together with their splitting pattern (s =
singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, m = multiplet),
coupling constant (J, Hz) and integration. MS were recorded using a Waters Acquity
tandem quadrupole (TQD) instrument with electrospray ionization. Infrared spectra were
obtained on a Thermo Nicolet iS10 FT-IR spectrophotometer. Microanalyses were
performed by Atlantic Microlab Inc. (Norcross, GA) for the indicated elements and results
are within 0.4% of calculated values. Reactions were routinely monitored by thin-layer
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chromatography (TLC) using silica gel GHLF plates (250 mm, 2.5 x 10 cm; Analtech Inc.
Newark, DE), and flash chromatography was performed on a CombiFlash Companion/TS
(Teledyne Isco Inc. Lincoln, NE). All final compounds were prepared as water-soluble
hydrochloride salts.

2-(3,4-Dichlorobenzoyl)piperidine Hydrochloride (119). 1-Bromo-3,4 dichlorobenzene
(125; 0.50 g, 2.2 mmol) was dissolved in anhydrous Et2O (7 mL) under an N2 atmosphere
and cooled to -78 °C (acetone : dry ice) and then 2.5 M n-BuLi in hexane (1.8 mL, 4.4
mmol) was added in a dropwise manner over 15 min. The reaction mixture was stirred at
-78 °C for 3 h to give intermediate 128. In another flask a stirred solution of 124 (0.59 g,
2.2 mmol) in Et2O (5 mL) under an N2 atmosphere was cooled to -29 °C (o-xylene : dry
ice) and then 128 was added in a dropwise manner over 15 min. The reaction mixture
was stirred at -29 °C for 3 h and allowed to warm to room temperature with continued
stirring for 12 h. The reaction mixture was quenched using cold 1 M KH2PO4 (20 mL),
extracted with EtOAc (3 x 30 mL), dried over MgSO4, filtered, and evaporated under
reduced pressure to produce a yellow oil that was chromatographed on silica gel 10 : 0 –
7 : 3 hexane : EtOAc. The collected fractions were combined and concentrated under
reduced pressure. The concentrate was dissolved in anhydrous Et 2O and cooled in an
ice bath. Anhydrous methanolic HCl was added in a dropwise manner until pH=1. The
solution was stirred overnight and evaporated to dryness. Washing with acetone then
recrystallization from MeOH gave 0.07 g of 119 as a white solid (12% yield): mp 272-273
°C (lit.7 mp 273-275 °C); 1H NMR (DMSO-d6 , 400 Mhz) δ 1.42–1.45 (m, 1H, CH2), 1.65–
1.77 (m, 4H, 2 x CH2), 2.06–2.09 (d, 1H, J = 12 Hz, CH2), 2.92–2.95 (d, 1H, J = 12 Hz,
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CH2), 3.33–3.36 (d, 1H, J = 12 Hz, CH2), 5.13–5.18 (m, 1H, CH), 7.89-7.92 (m, 1H, ArH), 8.01–8.03 (m, 1H, Ar-H), 8.30–8.31 (m, 1H, Ar–H), 8.97-8.98 (br d, 1H, NH), 9.539.64 (br d, 1H, NH+); IR (diamond, cm–1) 1685 (C═O); HRMS (ESI-TOF) m/z [M + H]+
calcd for C12H13NOCl2, 258.0452; found, 258.0439; Anal. Calcd for C12H13NOCl2·HCl: C,
48.92; H, 4.79; N, 4.75. Found: C, 48.81; H, 4.80; N, 4.77.

2-(3,4-Dimethylbenzoyl)piperidine Hydrochloride (120). 4-Bromo-o-xylene (126; 0.35
mL, 2.6 mmol) was dissolved in anhydrous Et2O (5 mL) under an N2 atmosphere and
cooled to 0 °C (ice-bath) and then 2.5 M n-BuLi in hexane (1.3 mL, 3.1 mmol) was added
in a dropwise manner over 15 min. The reaction mixture was stirred at 0 °C (ice bath) for
3 h to give intermediate 129. In another flask a stirred solution of 124 (0.20 g, 1.8 mmol)
in Et2O (5 mL) under an N2 atmosphere was cooled to -29 °C (o-xylene : dry ice) and then
129 was added in a dropwise manner over 15 min. The reaction mixture was stirred at 29 °C for 3 h and then allowed to warm to room temperature with continued stirring for 12
h. The reaction mixture was quenched using cold 1 M KH2PO4 (25 mL), extracted with
EtOAc (3 x 30 mL), dried over Na2SO4, filtered, and evaporated under reduced pressure
to produce a yellow oil that was chromatographed on silica gel 9.5 : 0.5 hexane : EtOAc.
The collected fractions were combined and concentrated under reduced pressure. The
concentrate was dissolved in anhydrous MeOH and cooled in an ice-bath. Anhydrous
methanolic HCl was added in a dropwise manner until pH=1. The solution was stirred
overnight and evaporated to dryness. Washing with acetone then recrystallization from
EtOH gave 0.12 g of 120 as a white solid (27% yield): mp 262-264 °C; 1H NMR (DMSOd6, 400 Mhz) δ 1.48(m, 1H, CH2), 1.82(m, 4H, 2 x CH2), 2.11(d, 1H, J = 16 Hz, CH2),
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2.38(s, 6H, 2 x CH3), 3.01(d, 1H, J = 12 Hz, CH2), 3.40(d, 1H, J = 16 Hz, CH2), 5.11(m,
1H, CH), 7.42(m, 1H, ArH), 7.85(m, 1H, ArH), 7.89(s, 1H, ArH), 8.94(br s, 1H, NH), 9.81(br
s, 1H, NH+); IR (diamond, cm–1) 1683 (C═O); HRMS (ESI-TOF) m/z [M + H]+ calcd for
C14H19NO, 218.1545; found, 218.1536.

2-(Naphtho-2-yl)piperidine Hydrochloride (121). 2-Bromonaphthalene (127; 0.50 g,
2.43 mmol) was dissolved in anhydrous Et2O (10 mL) under an N2 atmosphere. The
stirred mixture was cooled to -78 °C (acetone : dry ice). n-BuLi in hexanes (2.5 M, 5.93
mL, 4.83 mmol) was added in a dropwise manner over 15 min. The reaction mixture was
stirred at -78 °C for 3 h to give intermediate 130. In another flask a stirred solution of 124
(0.62 g, 2.74 mmol) in Et2O (5 mL) under an N2 atmosphere was cooled to -23 °C (CCl4 :
dry ice bath). Compound 130 was added in a dropwise manner over 15 min. The reaction
mixture was stirred at -23 °C (CCl4 : dry ice bath) for 3 h and then allowed to warm to
room temperature with continued stirring for 12 h. The reaction mixture was quenched
using cold 1 M KH2PO4 (20 mL), extracted with EtOAc (3 x 30 mL), dried over MgSO4,
filtered, and evaporated under reduced pressure to produce a yellow oil that was
chromatographed on silica gel 10 : 0 – 2 : 8 hexane : EtOAc. The collected fractions were
combined and stirred in anhydrous methanolic HCl overnight and evaporated to dryness.
Recrystallization from MeOH gave 0.13 g of 121 as a white solid (20% yield): mp 245247 °C; 1H NMR (DMSO-d6, 400 Mhz) δ 1.49–1.59 (q, 1H, CH2), 1.73–1.89 (m, 4H, 2 x
CH2), 2.19–2.23 (d, 1H, J = 16 Hz, CH2), 3.00–3.06 (t, 1H, J = 12 Hz, CH2), 3.34–3.40 (t,
1H, J = 12 Hz, CH2), 5.27–5.30 (d, 1H, J = 12 Hz, CH), 7.67-7.76 (m, 2H, Ar-H), 8.03–
8.07 (m, 2H, Ar-H), 8.10–8.13 (d, 1H, J = 12 Hz, Ar–H), 8.17–8.19 (d, 1H, J = 8 Hz, Ar–
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H), 8.85 (s, 1H, Ar–H), 9.00 (br s, 1H, NH), 9.86 (br s, 1H, NH+); IR (diamond, cm–1) 1674
(C═O); HRMS (ESI-TOF) m/z [M + H]+ calcd for C16H18NO, 240.1383; found, 240.1374.

N-Boc-pipecolic acid (123). Pipecolic acid (122) (2.0 g, 15.5 mmol) was added to MeOH
(22 mL) followed by the addition of Et3N (2.4 mL, 17.2 mmol). Room temperature (Boc)2O
(7.12 mL, 31.0 mmol) was then added to the stirred reaction mixture via syringe. The
reaction mixture was stirred for 1 h at room temperature. The mixture was then
concentrated under reduced pressure and suspended between EtOAc (75 mL) and sat.
NaHCO3 (75 mL). The organic layer was extracted with sat. NaHCO3 (2 x 30 mL) and
H2O (30 mL). The aqueous portions were combined and brought to pH 2 using 3 M HCl
and extracted with EtOAc (4 x 30 mL). The combined organic portion was dried over
MgSO4, filtered, and evaporated under reduced pressure to yield 3.4 g of N-Boc-2pipecolic acid (123) as a white solid (95% yield): mp 130-133 °C. (lit.67 123-124 °C).

N-Boc-pipecolate N-(methylmethoxyl)amide (124). N-Boc-2-pipecolic acid (123; 3.38
g, 14.7 mmol) was dissolved in DCM (50 mL) followed by the addition of N,Odimethylhydroxylamine hydrochloride (1.72 g, 17.7 mmol) and Et3N (7.18 mL, 51.5 mmol).
BOP (7.16 g, 16.2 mmol) was then added and the mixture was stirred at room temperature
for 16 h. The reaction mixture was then diluted with DCM (150 mL) and added to a
separatory funnel containing 1 M HCl (75 mL). The organic layer was washed with sat.
NaHCO3 (3 x 30 mL), brine (2 x 30 mL), H2O (2 x 30 mL), and 5% HCl (2 x 30 mL), dried
over MgSO4, filtered, and evaporated under reduced pressure. The resultant oil was then
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chromatographed on silica gel 4 : 1 hexanes : EtOAc to give 3.35 g of 124 as a colorless
oil that crystallized to a white solid over 48 h (84% yield): mp 64-66 °C (lit.94 66-68 °C).

2-(1-Pentoyl)piperidine Hydrochloride (132) 4-Bromo-o-xylene (126; 0.35 mL, 2.6
mmol) was dissolved in anhydrous Et2O (5 mL) under an N2 atmosphere and cooled to 78 °C (acetone : dry ice) and then 2.5 M n-BuLi in hexane (2.08 mL, 5.2 mmol) was added
in a dropwise manner over 15 min. The reaction mixture was stirred at -78 °C for 3 h to
give intermediate 128. In another flask a stirred solution of 124 (0.57 g, 2.6 mmol) in Et2O
(5 mL) under an N2 atmosphere was cooled to -29 °C (o-xylene : dry ice) and then 128
was added in a dropwise manner over 15 min. The reaction mixture was stirred at -29 °C
for 3 h and allowed to warm to room temperature with continued stirring for 12 h. The
reaction mixture was quenched using cold 1 M KH2PO4 (20 mL), extracted with EtOAc (3
x 30 mL), dried over MgSO4, filtered, and evaporated under reduced pressure to produce
a yellow oil that was chromatographed on silica gel 10 : 0 – 7 : 3 hexane : EtOAc. The
collected fractions were combined and concentrated under reduced pressure. The
concentrate was dissolved in anhydrous Et2O and cooled in an ice bath. Anhydrous
methanolic HCl was added in a dropwise manner until pH=1. The solution was stirred
overnight and evaporated to dryness. Washing with acetone then recrystallization from
MeOH gave 0.13 g of 132 as a white solid: mp 162-163 °C; 1H NMR (DMSO-d6 , 400
Mhz) δ 0.87 (s, 3H, CH3), 1.26–1.28 (m, 2H, CH2), 1.48–1.68 (m, 7H, CH2), 2.21–2.24
(m, 1H, CH2), 2.59 (m, 1H, CH2), 2.78-2.84 (m, 1H, CH), 3.19 (d, 1H, J = 12 Hz, CH2),
4.01-4.04 (dd, 1H, J = 12 Hz, CH), 9.22-9.28 (br s, 1H, NH), 9.22-9.28 (br s, 1H, NH+);
HRMS (ESI-TOF) m/z [M + H]+ calcd for C12H13NOCl2, 170.1544 found 170.1535.
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C. APP+ Uptake Assay
1. Preparation of HEK293 cells
A HEK293 Flp-In T-REx cell line stably expressing hDAT was developed previously in the
laboratory.46 Cells were prepared in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum and hygromycin. The cells were plated on 96well plates and were transiently transfected with red fluorescent protein (DsRed, TaKaRa
Bio USA, Mountain View, CA) which is used to focus cells to a monolayer plane in the
fluorescence microscope before the addition of APP+. Doxycycline (1 g/mL) was added
to the culturing media 3 days before the experiment to induce expression of DAT.

2. Solution for the experiment
Imaging solution (IS) was prepared and was used to dissolve all the analogs and as a
vehicle. It consisted of NaCl (130 mM), KCl (4 mM), CaCl2 (2 mM), MgCl2 (1 mM), Hepes
(10 mM), and glucose (10 mM). The pH of the IS was adjusted between 7.3-7.4 using a
saturated solution of NaOH.

3. Agents
threo-Methylphenidate was purchased as its hydrochloride salt from
Sigma-Aldrich, St. Louis, MO.
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4. Live-cell imaging
The cells were placed on the stage of the epifluorescent microscope (Olympus IX71)
equipped with a light source DeltaRAM X Random Access Monochromator (HORIBA
Scientific, Piscataway, New Jersey), a Lightning-Cam camera (HORIBA Scientific,
Piscataway, New Jersey), and an automated perfusion system Pressurized Superfusion
(AutoMate Scientific, Berkeley, California) regulated by Clampex 10.2 (Molecular
Devices, San Jose, California). The imaging system was coordinated using the
EasyRatioPro 3 (HORIBA Scientific, Piscataway, New Jersey). The entire experiment
was done at room temperature. The DsRed signal of transfected cells were used to find
the focal plane of the cell monolayer. The wavelength of 460 nm was used for excitation
of the APP+ and 540 nm to detect the emission. The experiment consisted of three
phases over 70 seconds and was under constant perfusion. The cells were exposed with
the IS for 10 seconds followed by the compound of interest for 30 seconds and finally
compound of interest plus APP+ (3 μM) for 30 seconds. All the hybrid analogs were
evaluated at six different concentrations in order to obtain a complete dose-response
curve.

5. Analysis
The data obtained from the APP+ assay were analyzed using EasyRatioPro 3 (HORIBA
Scientific, Piscataway, New Jersey) and the dose-response curves were plotted using
GraphPad Prism 8.0.
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